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CHAPTER I 
 
INTRODUCTION 
 
           Siddha is one of the ancient medical systems in India considered as the mother 
medicine of ancient Dravidians in South India. The word Siddha means established truth or 
"one who is accomplished". 
The term „Siddhar‟ has derived from the word „siddhi‟ which literally, means 
accomplished, achieved, or perfected success; and so it refers to one who had attained his 
end in spiritual goal. The word „Siddha‟ does not refer to those men who have become free-
a sense in which it is often used. 
          The Siddhar‟s had investigated and studied the cause and effect of disease and all 
kinds of drugs, mineral and poisons and thereby came to realize what is beneficial and what 
was not to their existence in life. They can even, if they choose retain their bodies for ages 
of disintegrate them at their will and can also dematerialize or rematerialize their bodies as 
they liked.
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           In Siddha medicine the use of metals and minerals are more predominant in 
comparison to other Indian traditional medicine systems.The drugs used by the Siddhar‟s 
could be classified into three groups: Mooligai/Thavaram (herbal product), Thathu 
(inorganic substances) and Jeevam or Sangamam (animal products). The Thathu drugs are 
further classified as:  
 
1. Loham (Heavy metals)  
2. Paashanam (Arsenicals)  
3. Uppu (Salts)  
4. Rasam (Mercury and its salts)  
 
      The use of more metals and chemicals was justified by the fact that to preserve the body 
from decomposing materials and it has more potency to treat the chronic diseases. One 
among the metal is Ayam which is commonly used by Siddha practitioners for treating 
various diseases.  
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According to their mode of application the Siddha medicine could be categorized into two 
classes: 
 1. Internal medicine and 
 2. External medicine.  
 
 Internal medicines are used through the oral route and further classified into 32 
categories based on their form, method of preparation, shelf life, etc. 
 External medicine includes certain form of drugs and also certain applications like 
nasal, eye and ear drops and also certain procedures like leech application.  
 
The internal medicines are 32 in number. They include medicines with short life period 
to medicines which could be used even for hundreds of years. The metallic preparations that 
could be preserved and used for longer duration are considered as higher medicines. They 
act even in very small quantity and are capable of curing chronic illness. Elagam was one 
among them. 
 
In Siddha literature Elagam maens some decoctions or juices are mixed together, sugar 
is added to it and boiled in the mild fire. When an aromatic smell appears, fine powders are 
sprinkled into it. Ghee is added to it and then, honey is added until it is mixed well.
2 
 
Ayapodi Elagam is one among the elagam preparation in Siddha system of medicine. 
The ingredient of the drug was Ayam, Nellikai, Keezhanellai and Karisalai. It is used for 
treating anaemia, jaundice etc.It impoves and purifies the blood. Iron is the most important 
metal used in Siddha system of medicine for treating pandu. The Siddha medicines meant 
for the human body are prepared, based on the theory of Panchabootham.The metals also 
calcified based on panchabootham theory. 
 Gold–Earth 
 Lead  – Water 
 Copper – Fire 
 Iron  – Air 
 Zinc  –Space 
 
 Gold and lead are used for the maintenance of the body. Iron, the only metal attracted by 
the electric power of the magnet, and zinc used for generating electricity are employed in 
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the medicines which are administered for the extension of life and copper is used for the 
preservation of heat in the body.  
 
 The external five elements correspond to the internal Vatham, Pitham, and Kaphamof the 
human body. This concept is described by the great sage Sattamuni as,          
 
அண்டத்஡ில் உள்பத஡ோ திண்டம் 
 திண்டத்஡ில் உள்பத஡ோ அண்டம். 
 
    The treatments for the imbalance of the three humors are made up of the five 
elements. The drugs are made up of the five elements. By substituting a drug of the same 
constituents (gunam) the equilibrium is restored. The correction of the imbalance is made 
by substituting the drug which is predominate of the opposite nature.
3
 
 
Pandu is a pitham related disease.So the medicine which is used for the treatment of 
pandu that medicine has to balance the deranged pitham in our body
4
. 
 
Anaemia is the most prevalent nutritional deficiency disorder in the world. It is a 
condition that occurs when the red blood cells do not carry enough oxygen to the tissues of 
the body.  
 
According to World Health Organization criteria, anemia is defined as blood hemoglobin 
(Hb) concentration <130 g/L (<13 g/dL) or hematocrit (Hct) <39% in adult males; Hb <120 
g/L (<12 g/dL) or Hct<37% in adult females. 
 
A physiologic approach to anaemia diagnosis is based on the understanding that a decrease 
in circulating RBCs can be related to either inadequate production of RBCs or increased 
RBC destruction or loss. Within the category of inadequate production, erythropoiesis can 
be either ineffective, due to an erythrocyte maturation defect, or hypoproliferative.
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Most of the anemias are due to an inadequate supply of nutrients like iron, folic acid 
and vitamin B12, proteins, amino acids, vitamins A, C, and other vitamins of  B-complex 
group i.e., niacin and pantothenic acid are also involved in the maintenance of haemoglobin 
level. 
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  Globally, anaemia affects 1.62 billion people, which corresponds to 24.8% of the 
population. The highest prevalence is in preschool-age children (47.4%), and the lowest 
prevalence is in men (12.7%). 
 
            Prevalence of anaemia in all the groups is higher in India as compared to other 
developing countries.In India anaemia affects an estimated 50% of the population. The 
problem becomes more severe as more women are affected by it as compared to men.
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According to Siddha literature lot of Ayam containing preparations are mentioned for 
treating pandu. One of the medicine is Ayapodi Elagam. In this medicine not only in Ayam 
the ingredients like Karisalai, Nellikai and Keezhanelli also used for treating pandu.It is 
used by many Siddha practitioners,yet this safety  is not proven. 
 
So I proposed to take Ayapodi Elagam for my dissertation study to evaluate the 
safety profile on animal model. 
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CHAPTER II 
AIM AND OBJECTIVES 
 
AIM:  
To evaluate the safety profile of Ayapodi Elagam (A.E) on animal model 
(wistaralbino rats). 
OBJECTIVES: 
 To study the physicochemical properties, biochemical analysis and phytochemical 
analysis of Ayapodi Elagam(A.E). 
 To study the spectroscopic analysis of Ayapodi Elagam(A.E). 
 To evaluate the acute toxicity profile of Ayapodi Elagam as per WHO Guideline. 
 To evaluate the long term toxicity profile of Ayapodi Elagam as per WHO 
Guideline. 
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CHAPTER III 
அ஦ம் 
த஬றுபத஦ர்:      
             அகி, அ஦சு, அ஦ில், இடி, இபேம்பு, ஈசபச஦ம், கபேங்பகோல், கபேப்தி, கபேம்பு, 
கபேப்பு, கபே஥஠ல், கபேம்பதோன், க஦சு,கிபேஷ்஠வ஬஦ம், கோனில் ப஢கிபம், தனோகம், 
சிட்டம், பதோன்஥஠ல், சத்து, ஬ோழ்பூ஥ி ஢ோ஡ம்,திண்டம், கபேந்஡ோது. 
 
தவகச஧க்கு:  
 அப்தி஧கம், 
 அண்டத஬ோடு, 
 கந்஡ி, 
 பகௌரி, 
 சவ்஬஧ீம், 
 சோ஧ம், 
 சிங்கி, 
 சினோசத்து, 
 சிவன,஡஧ோ, 
 ப஬ங்கோ஧ம், 
 ப஬ள்வபப்தோடோ஠ம். 
஢ட்புச஧க்கு:  
 கோந்஡ம், 
 சூடன், 
 பசம்பு, 
 ஡ங்கம், 
 ஢ோகம், 
 பூ஧ம், 
 ப஬ள்பி, 
 பூ஢ோகம், 
 ஥பெ஧ச்பசம்பு 
சுவ஬ :  து஬ர்ப்பு, சிறு புபிப்பு,வகப்பு 
஡ன்வ஥:  ப஬ப்தம் 
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பசய்வக:  
தசிப௅ண்டோக்கி 
உடல் உ஧஥ோக்கி 
குபே஡ிபதபேக்கி 
உடல்த஡ற்நி 
 
கு஠ம் : 
 “தோண்டுப஬ண் குட்டம் தபேந்தூன த஢ோய்தசோவத 
 ஥ோண்டிடச்பசய் ஥ந்஡ங்கோ ஥ோவனகுன்஥ம் பூண்ட 
 பதபேந்஡ோது ஢ட்டப௃ம்ததோம் தத஡ிதசி ப௅ண்டோங் 
கபேந்஡ோது ஢ட்ட஥ிடுங் கோல்”. 
 
இபேம்திணோல் தித்஡ப்தோண்டு, ப஬ண் குட்டம், அ஡ிதூனத஢ோய், தசோவத, ஥ந்஡ம், 
கோ஥ோவன, குன்஥ம், சுக்கின஢ட்டம், க஫ிச்சல்,இவ஬ ஢ீங்கும்,தசி உண்டோகும். 
 
த஫ப஥ோ஫ிகள்: 
“இவபத்஡஬ர் இபேம்வத உண்஠ த஬ண்டும்” 
“஋ய்ப்புடற் கிபேம்வத ப௅ண்஥ின்” 
 
சுத்஡ிப௃வநகள்:  
1. எபே தனம் அ஦ப்பதோடிக்கு ஆறு தனம் இலுப்வதப் பூச்சோறு ஬ிட்டு. கோவன 
ப௃஡ல் ஥ோவன ஬வ஧ ப஬஦ினில் வ஬க்க த஬ண்டும். இவ்஬ி஡ம் ஆறு ஢ோள் 
பசய்து இ஧ண்டு ஢ோள் சோறு ஬ிடோ஥ல் உனர்த்஡ி , தின்னும் இவ஡ப் ததோன  
இபேப௃வந பசய்து, 25 ஆம் ஢ோள் ப௃஡ல் 10 ஢ோட்கள் இவட஬ிடோ஥ல் த஥ற்தடி 
சோறு஬ிட்டு, ப஬ய்஦ினில் வ஬த்துப் தின்பு, சோறு஬ிடோ஥ல் இ஧ண்டு ஢ோள் 
உனர்த்஡ி ஢ீர்஬ிட்டுக் கழு஬ி ஋டுக்கச் சுத்஡ி஦ோம். 
 
2. அ஦த்வ஡க் பகோல்னன் உவன஦ினிட்டுச் சி஬க்க கோய்ச்சி ,ஆறு஥ோ஡ 
அன்ணக்கோடி, ஋ண்ப஠ய், ஆ஬ின்஢ீர், பகோள்குடி஢ீர் இந்஢ோன்கிலும் ப௃வநத஦ 
ப௃ம்ப௄ன்று ப௃வந த஡ோய்த்துத் த஡ோய்த்ப஡டுத்துக் கழு஬ிக் பகோள்பச் 
சுத்஡ி஦ோம். 
 
3. இபேம்தின் அ஧ப்பதோடிவ஦ ஋லு஥ிச்வச த஫ச்சோறு, கோடி, ஢ோட்டுக் 
கோட்டோ஥஠க்குப் தோல் இவ஬ எவ்ப஬ோன்நிலும் ப௄ன்று ஢ோள் ஊந 
வ஬த்துக் கழு஬ிப஦டுக்கச் சுத்஡ி஦ோம். 
 
4. அ஦ப்பதோடிக்கு ஢ோ஬ற்த஫ச் சோற்வந ப௄ழ்கும்தடி ஬ிட்டு சோறு சுண்டும் ஬வ஧ 
ப஬஦ினில் வ஬த்துக் கழுவுக. இவ்஬ி஡ம் ஆறுப௃வந பசய்஦ அ஦ம் 
சுத்஡ி஦ோம். 
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5. இபேம்புப்பதோடிவ஦ எபே ஢ோள் த஫஧சத்஡ில் ஊநவ஬த்து ஋டுத்து ஥று஢ோள் 
஋ண்ப஠஦ில் ஊநவ஬த்து அ஦ச்சட்டி஦ில் ததோட்டு ஬றுத்து கோடி஦ில் கழு஬ி 
த஬னம்தட்வட கி஦ோ஫த்஡ில் பகோ஡ிப்தித்து஡ிபேம்தவும் கோடி஦ில் கழு஬ி 
஋டுத்துக்பகோள்பவும். 
 
த஡ோடம் : 
அ஦த்஡ிற்கு ஍ந்த஡ோடங்கள் உண்டு. 
“஬ோறுதக பிபேம்புக்வகங் கு஠ங்க ல௃ண்டு 
஬வக஦ோகச் பசோல்லுகிதநன் ஢ன்நோய்க் தகல௃ம் 
 ஡ோறுதகள் ஡ிவ஧ச஬ிடு வுவடச்ச லூநல் 
  ச஧ச஥ோ ஦ிபேக்கோ஡ கு஠ந்஡ோ வணந்தும் 
ததறுதக பிவ஡஢ீக்க ஬நிந்த஡ோன் ஬ோ஡ி 
  திரித்஡ி஡வண ஢ீக்கோ஡ோன் தி஠ந்஡ோன் தோத஧ 
஬ோறுதகள் குபம்ப஬ட்ட வூற்றுப் ததோன  
  ஬ம்஥ம்஥ோ ஬ிபேம்பூநல் அபேகோ ப஡ன்தண.” 
 
சுத்஡ி பசய்஦ப்தட்ட அ஦த்வ஡ப் தற்தம், பசந்தூ஧ம், கபங்கு, ப஥ழுகு,஬டகம், 
தோ஠ி஡ம் ப௃஡னி஦ ஥பேந்துகபோக்கி உதத஦ோகித்஡ல் த஬ண்டும். 
 
இ஬ற்றுள், தற்தம்   –  ப௃ழு஬ன்வ஥ப௅ம் 
     பசந்தூ஧ம்   –  ப௃க்கோல் ஬ன்வ஥ப௅ம்  
 ஥ற்ந ஥பேந்துகள் –  அ஡ற்கும் குவநந்஡ ஬ன்வ஥ப௅ம்பகோடுக்கும்.2 
 
அ஦ம் தசபேம் திந ஥பேந்துகள்:  
 
1.அ஦ச்பசந்தூ஧ம் 8 
 அபவு   : து஬வ஧஦பவு 
 அனுதோணம்   : ஡குந்஡அனுதோணம் 
 ஡பீேம்த஢ோய்   : ஡ோது஬ிபேத்஡ி, ஢ல்னத஡ஜசம் உண்டோகும் 
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2.அ஦கோந்஡ பசந்தூ஧ம்9 
 
 அபவு  :  ½ ப௃஡ல் 1 குன்நி(65-130mg) 
 ஡பீேம்த஢ோய்  :  தோண்டு, தசோவத,சு஧ம் 
 
3.அ஦கோந்஡சண்ட஥ோபே஡ச் பசந்தூ஧ம் 
 
 அபவு  :  ½ ப௃஡ல் 1 குன்நி(65-130mg) 
 ஡பீேம்த஢ோய்  :  தோண்டு, தசோவத,கோ஥ோவன 
 
4.஬஧ீஅ஦ச்பசந்தூ஧ம்  
 அபவு  :  ½ ப௃஡ல் 1 குன்நி(65-130mg) 
 அனுதோணம்  :      ப஢ய்,த஡ன், ப஬ண்ப஠ய் 
 ஡பீேம்த஢ோய்  :  தோண்டு, தசோவத,கோ஥ோவன 
 
5.஢ீனகண்ட பசந்தூ஧ம் 
 அபவு  :  2 அரிசி 
 அனுதோணம்  :  ப஢ய், த஡ன் 
 ஡பீேம்த஢ோய்  :  தோரிச஬ோ஡ம், ப௃க஬ோ஡ம், ஜிக்கு஬ோ஡ம் 
 
6.஬ங்கச் சந்஡ித஧ோ஡஦ம் 
 அபவு  :  1\4 ப௃஡ல் 1\2 குன்நி(32.5-65mg) 
 அனுதோணம்  : ஡ிரிகடுகு சூ஧஠ம் 
 ஡பீேம்த஢ோய்  :  தித்஡ம், ஬ோப௅, அக்கிணி஥ந்஡ம், கோ஥ோவன,  
தசோவத 
 
7.சத்து பசந்தூ஧ம்  
 அபவு  :  1\4 குன்நி(32.5mg) 
 அனுதோணம்  :  ப஢ய், த஡ன் 
 ஡பீேம்த஢ோய்  :  ஢஧ம்தின் துர்தனம், இ஧த்஡குவநவு, ஥துத஥கம் 
 
8.அ஦ச்சூ஧஠ம்10 
 அபவு  : குன்நிப஦வட(130mg) 
 அனுதோணம்  : ப஢ய், த஡ன் 
 ஡பீேம்த஢ோய்  : ஋ல்னோ஬வகதோண்டு, கி஧ோ஠ிகள் 
 
9.சு஦஥ோக்கிணி 
 அபவு  :  2-3 குன்நி(260-390mg) 
 அனுதோணம்  :  ப஢ய், த஡ன், இஞ்சி இபகம் 
஡பீேம்த஢ோய்  : குன்஥ம், பதபேங்க஫ிச்சல், அக்கிணி஥ந்஡ம், சுவ஬஦ின்வ஥ 
 
10. தனோக பசந்தூ஧ம்  
 அபவு  :  2-3 குன்நி(260-390mg) 
 அனுதோணம்  :  ப஢ய், த஡ன் 
 ஡பீேம்த஢ோய்  :  தித்஡ப஬ட்வட, ஥ஞ்சள்த஢ோய், ஢ச்சுதத஡ி, அசி஧஠ம் 
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11.஬பே஠தனோக பசந்தூ஧ம்  
 
 அபவு  :  1\4 ப௃஡ல் 11\2 குன்நி(32.5-195mg) 
 அனுதோணம்  :  த஡ன், ப஢ய் 
 ஡பீேம்த஢ோய்  : தோண்டு, கோ஥ோவன 
 
12.சுண்஠தனோக பசந்தூ஧ம்  
 
 அபவு  :  1 1\2 - 3 குன்நி(195-390mg) 
 அனுதோணம்  :  த஡ன், ப஢ய், ப஬ள்பரி஬ிவ஡ 
 ஡பீேம்த஢ோய்  :  தோண்டு, தீனிவக, பதபே஬஦ிறு 
 
13. ஋ஃகுசு஬ர்஠பசந்தூ஧ம்  
 
 அபவு  :  1 – 2 அரிசி 
 அனுதோணம்  : த஡ன், தோதனடு,தகோதுவ஥தோல் 
஡பீேம்த஢ோய்  :  தோண்டு, அச஡ி, ச஦ம், ப௄வப஢னக்குவநவு,  
இ஧த்஡ங்கக்கல்10 
 
14. அ஦த்஡ங்கச் பசந்தூ஧ம்9 
 
 அபவு  :  1\2  ப௃஡ல் 1 குன்நி( 65-130mg) 
 அனுதோணம்  :  த஡ன், ப஢ய் 
 ஡பீேம்த஢ோய்  : கோசம், தோரிச஬ோ஡ம்,ப௃க஬ோ஡ம்,கோ஥ோவன,  
஥துத஥கம் 
 
15. அ஦ப஬ள்பிச் பசந்தூ஧ம் 
 
 அபவு  : து஬வ஧஦பவு 
 அனுதோணம்  :  ஡ோது஬ிபேத்஡ிதனகி஦ம் 
 ஡பீேம்த஢ோய்  :  ஢ோட்தட்டத஡கதுர்தனம்,஡ோது஢ட்டம் 
 
16. சின்ணதட்டுக்கறுப்பு 
 
 அபவு  :  து஬வ஧஦பவு 
 அனுதோணம்  : த஡ன் 
 ஡பீேம்த஢ோய்  : த஥கசு஧ம்,஦ோவணகோல்,சு஧ம்,஬஦ிற்று஬னி. 
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AYAM (FERRUM) 
 
Eng : Iron 
Sans :  Lauha 
Tam :  Irimbu  
Tel :  Inumu 
Hind :  Loha 
Urdu :  Lohchum  
 
Source:     
Rarely met with free in nature, though very widely distributed in both organic and 
inorganic kingdom.Founds nearly all rocks, soils, etc., variously combined with oxygen as 
haematite, magnetic iron ore etc., with sulphur as iron- pyrites, and as a carbonate of iron, in 
spathi iron; in the ashes of plants and even the blood of animals; also in the bile, chyle, 
gastric juice, lymph, milk, pigment of  the eye and in the urine.
11
 
 
Iron ores: 
             Next to the aluminium iron is the most abundant metallic element comprising about 
4.44% of the earth crust. It does not occur in the metallic form except rarely in meteorites. It 
is found mainly in the form of oxides hydrated oxides, carbonates, sulphides, silicate and 
hydrated oxides of iron and aluminium. Chromites and ilmenite are iron-bearing 
minerals.Iron is sometimes obtained as a byproduct in the working of pyrites and ilmenite. 
 
Origin and mode of occurrence:  
 
             Only a few of the world‟s iron ore deposits are of igneous origin .The great majority 
of them have been formed by deposition from sulphur or underground waters. The iron 
being normally derived by solution from preexisting rocks under ordinary temperature 
conditions.In some cases the iron minerals have been concentrated in the form of iron sands. 
Electrolytes occurring in natural waters may also precipitate iron. 
 
             Compared most producing countries the quality of iron ores mined in India is 
superior. India iron ore deposits are among the finest and largest in the world the average 
ore worked at present containing over 60% iron. 
13 
 
 
In Tamilnadu: 
            Iron ore deposits of some importance occur in Salem and Tiruchirapalli districts. 
Several occurrences in other districts are known but they are not considered important at 
present. 
            Salem and Tiruchirapalli extensive deposits of magnetite quartz rocks occur in a 
series of ridges and hillocks in these districts. The major deposits are kanjamalai, 
godumalai, perunamalai, pachamalai, kollimalai and chitteri.Deposits are also found in 
several hills 5 miles west south-west of the Salem town is the most important the average 
iron content is 35- 40%. Grade % of iron in Madras 67 and above.
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Physical properties: 
Iron is a silvery white or greyish metal. It is ductile and malleable. Ductile means capable of 
being drawn into thin wires. Malleable means capable of being hammered into thin steels. It 
is one of only three naturally occurring magnetic elements. The other two are nickel and 
cobalt. 
Chemical properties: 
Iron is a very active metal. It readily combines with oxygen in the moist air. The product of 
this reaction iron oxide is known as rust. Iron also reacts with very hot water and steam to 
produce hydrogen gas. It also dissolves in most acids and reacts with many other 
elements.Iron burns with a gold colour in a flame test.
13
 
In Siddha aspect: 
              Iron is found in mountains and in the earth in association with certain material like 
sulphur. It is also found in some plants and animals. 
              Iron has astringent and mild sour and bitter taste. It has tonic, haemopoietic, 
appetite, stimulant and health-promoting properties. It potency is hot.  
              It improves the properties and functions of blood. Some preparations of iron may 
cause constipation. In order to prevent it the myrobalans are added to iron preparations.  
Iron stimulates the functions of all the organs of the body and thus it acts as a tonic. 
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              Iron preparations are used in treating the disease like anaemia, jaundice, 
leucoderma, obesity, dropsy, anorexia, peptic ulcer, spermatorrhoea, diarrhoea and 
dyspepsia.
14 
Iron in modern aspect: 
           Iron is an essential nutrient utilized in almost every aspect of cell function and its 
availability has previously limited life. Those same properties which allow iron to function 
as a catalyst in the reactions of life also present a threat via generation of oxygen-based free 
radicals. Accordingly life exists at the interference of iron deficiency and iron sufficiency. 
Iron is an important “blood building mineral”.Blood protein such as haemoglobin transport 
iron in RBC. Hb is critical for iron, oxygen and CO2 transport. Iron in it‟s critical for the 
formation of catalyzing a key antioxidant that protects cells from free radicals by degrading 
hydrogen peroxide to water and O2. Inadequate iron means inadequate Hb means low TPO 
bonding which leads to anaemia.
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Recommended Daily intake: 
 Adult man      :  10 mg/day 
 Menstruating woman    :  18 mg/day 
 Pregnant and lactating woman: 40 mg/day
16 
 
Food: 
  Iron occurs as a natural constituent in plants and animals. Liver, kidney, fish, and 
green vegetables contain 20–150 mg/kg whereas red meats and egg yolks contain 10–20 
mg/kg. Rice and many fruits and vegetables have low iron contents (1–10 mg/kg). 
Estimated total exposureand relative contribution of drinking water. Reported daily intakes 
of iron in food - the major source of exposure range from 10 to 14 mg. Drinking water 
containing 0.3 mg/litre would contribute about 0.6 mg to the daily intake. Intake of iron 
from the air is about 25 μg/day in urban areas.17 
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Uses: 
 Iron is an essential mineral for health, but too much iron is extremely toxic. Free 
iron in the blood reacts with peroxides to form free radicals that damage DNA, 
protein, lipids and other cellular components, leading to illness and sometimes 
death. 
 
 20 milligrams of iron per kilogram of body weight is toxic, while 60 milligrams per 
kilogram is lethal. 
 
 Iron is essential for the development of brain in children. Children with iron 
deficiencies show a lower ability to learn.
13
 
 
 Iron improves the quality of blood. 
 
 Iron stimulates the functional activity of all the organs of the body and is therefore a 
valuable general tonic. 
 
 As a haematinic tonic prepared iron is used in many diseases like anaemia and 
chlorosis. 
 
 Iron has a great value in both simple and secondary anaemias.    
 
 In haemorrhagic diseases such as haemoptysis, haematuria, bleeding from piles 
etc.Iron is commonly given with good result. 
 
 In leucorrhoea leading to anaemia preparations containing iron are useful. 
 
 Iron oxides and hydroxides are used as pigments in cosmetics.  
 
 Potassium ferricyanide (red prussiates of potash) is obtained from ferrous 
ferricyanide (Turnbull‟s blue) and is used in processing blueprint paper. 
 
 The use of iron cooking utensils is often considered a useful source of 
supplementary iron in the diet.
18
 
 
 Iron is of great value when given internally in some skin diseases i.e., erysipelas, 
carbuncles and furunculosis. 
 
 In anaemia and dyspepsia with anorexia an organic compound of iron called kalpam 
made of iron powder, pepper, garlic and limes was tried and “found very beneficial 
in improving the blood strengthening the patient and also in creating an appetite”.11 
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Heavy metal toxicity: 
Symptoms of excess:  
 Anger, liver disease, cancer, iron deposits in organs, diabetes, arthritis, cirrhosis of 
the liver, schizophrenia, emotional problems, high blood pressure, myasthenia gravis, 
hemochromatosis and hemosiderosis.  
Additional Iron Factors:  Excess iron can lead to aggressive behaviour.
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Scientific validation: 
 
 This article reveals the iron increase the haemoglobin leavel.The dose of iron which 
produces an average increase of at least 1% of haemoglobin per day in a substantially 
large group of patients with achlorhydria and anaemia. To achieve this one must 
consume at least 25mg of iron.
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 Intravenous Iron therapy is effective in increasing the Hb concentration and reducing 
the risk of allogeneic red cell transfusion and could have broad applicability to a range 
of acute care settings. This potential benefit is counterbalanced by a potential 
increased risk of infection.
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 This article showed the toxic effect of the iron.Oral administration of Arumuga 
Chenduram did not induce any toxic effect at 24mg/kg/day dose in rats and this stands 
as an assurance of safety usage at its desirable human intended therapeutic dosage of 
260mg/70kg/day in the practice of Siddha medicine.
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 This article reveals the effectiveness of iron preparation.The Ayurvedic iron 
preparation Sahastrapatti lauha bhasma and Satiputti lauha bhasma may be considered 
to be better drugs that the allopathic iron preparation ferrous sulphate on the basis of 
the bioavailability resulting due to increase in the haemoglobin content.
23
 
 
 This article reveals the safety of the iron containing medicine. Lauha Bhasma and 
Mandura Bhasma in 55mg/kg dose for 60 days exhibited no serious toxic effects in 
Charles Foster Albino rats. Both the drugs showed significant recovery from chronic 
toxic effect after 45 days of the recovery period.
24
 
 
 The Acute LD of FeCl3 for sheep therefore seems to be between 2.0- 2.5g/kg while 
500mg/kg/day caused death within 3 weeks. A Dosage of 100mg/kg/day over 182 
days caused pronounced symptoms and marked accumulation of Fe in soft tissues. As 
little as 34 mg FeCl3/kg/day therefore causedas accumulation of Fe in soft tissues. It is 
therefore possible that even low dosages given over long periods might not be without 
danger.
25
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 This article showed the effect of iron containing medicine against the bacteria.  
Chandraprabhavati showed a significant reduction in signs and symptoms of 
Albuminuria mainly albumin in urine and although turbidity, organism, pus cells, red 
cells colour and frequency of urine as well as the same premonitory symptoms of 
prameha.
26
 
 
 This article reveals the cardio productive effect of iron.The Cardio productive activity 
of Fe2O3 NPs requires the integrity of Nanoparticles and is not dependent upon their 
surface changes and molecules that were integrated into nanoparticles. Also Fe2O3 
NPs showed no significant toxicity towards normal cardiomyocytes, indicative of their 
potential to treat cardiovascular disease.
27
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3.2 ப஢ல்னிக்கோய் 
த஬றுபத஦ர்: ஆ஥னகம்,  
ஆனகம்,  
ஆம்தல்,  
ஆ஥ரிகம்,  
஡ோத்஡ோரி, 
஡ோத்஡ிரி,  
தகோ஧ங்கம்,  
஥ிறுதுதனோ, 
஥ீதுந்து. 
 
த஦ன்தடும் உறுப்பு:  இவன, பூ, தட்வட,த஬ர்,கோய், ஬ிவ஡ 
சுவ஬  :   புபிப்பு, து஬ர்ப்பு, இணிப்பு 
஡ன்வ஥ :  ஡ட்தம் 
திரிவு  :   இணிப்பு 
பசய்வக:  
  து஬ர்ப்தி    –  Astringent  
சிறு஢ீர்ப்பதபேக்கி   –  Diuretic  
குபிர்ச்சிப௅ண்டோக்கி  –  Refrigerant 
       ஥ன஥ிபக்கி    -  Laxative 
 
கு஠ம்:  
 
“தித்஡஥ண வன஦ம் தீ஢சம்஬ோய் ஢ீர் ஬ோந்஡ி 
஥த்஡஥னக் கோடும் ஥஦க்கப௃஥ில் – எத்துவுபே 
஬ில்னிக்கோ ஦ம்஥பேங்கோ ப஥ன்ணோட்கோ னந்த஡ர்ந்த஡  
ப஢ல்னிகோ ஦ம்஥பேந் து஠”ீ. 
 
ப஢ல்னிக்கோவ஦ப் தகற்பதோழுதுண்஠ில் ப஬நி, ஍஦த஢ோய்,தீணிசம், ஬ோய்஢ீர் 
சு஧ப்பு,஬ோந்஡ி, ஥஦க்கம், ஡வனச்சு஫னல், ஥னதந்஡ம், தி஧த஥கம் இவ஬ ததோம். 
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஬஫க்குப௃வந: 
 
 ப஢ல்னிக்கோவ஦த் துவ஬஦ல் பசய்து சோப்திட சுவ஬஦ின்வ஥, ஬ோந்஡ி 
இவ஬கவப ததோக்கும். 
 ப஢ல்னி஬ற்நவனக் குடி஢ீர் பசய்து சோப்திட ஥஦க்கம், ஡ோகம், ஏக்கோபம் இவ஬ 
஢ீங்கும். 
 ப௄ப்தவடந்஡ ஬பேம் இபவ஥ப௅வட஦ ஥ோப்திவபப்ததோல் அ஫குடன் இபேக்க 
த஬ண்டின், ப஢ல்னிக்கோவ஦ தோகஞ் பசய்து உண்ட௃஡ல் த஬ண்டும். 
 இவனபகோழுந்வ஡ அவ஧த்து த஥ோரில் கனந்து ச஡ீக்க஫ிச்சலுக்குக் 
பகோடுக்கனோம். 
 ப஢ல்னி஬ற்நவன குடி஢ீர் பசய்து சணீி கூட்டிப் தோல் தசர்த்துச் சோப்திட சூடு, 
ஆண்குநிப்புண்,஬ோந்஡ி ஡பீேம்.28 
 ப஢ல்னி஬ற்நவன குடி஢ீர் பசய்து ஡ிணப௃ம் இபே த஬வப பகோடுத்து ஬஧ 
இ஧த்஡஥ின்வ஥, கோ஥ோவன, தித்஡குன்஥ம் ததோம்.  
 
ப஢ல்னிக்கோய் தசர்ந்஡ திந஥பேந்துகள்: 
 
1.திபேங்கோ஥னக வ஡னம்9 
 
 தி஧த஦ோகம்   :  ஸ்஢ோணம் பசய்஦ 
 ஡பீேம்த஢ோய்கள்  :  கண்ப஠ரிச்சல்,த஡க஋ரிவு,கண்த஠ோவு. 
 
2. ஊ஫ி ஥ோத்஡ிவ஧29 
 
 அபவு   :  குன்நி஦பவு (130 mg) 
 ஡பீேம்த஢ோய்கள்  :  ஊ஫ி,அ஡ிசோ஧ம்,கி஧ோ஠ி. 
 
3.ச஧ீகச்சூ஧஠ம் 
 
 அபவு   :  ப஬பேகடி஦பவு 
 அனுதோணம்   :  சர்க்கவ஧ 
 ஡பீேம்த஢ோய்கள்  :  ஬ோந்஡ி,அக்கிணி஥ந்஡ம்,உஷ்஠ம். 
 
4.சுண்வட஬ற்நல் சூ஧஠ம் 
 
 அபவு   :  ப஬பேகடி஦பவு 
 அனுதோணம்   :  ஋பேவ஥஡஦ிர் 
 ஡பீேம்த஢ோய்கள்  :  பதோபே஥ல்,஥ந்஡ம்,ப௄னம்,கி஧க஠ி 
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5.கந்஡க இ஧சோ஦஠ம்  
 
 அபவு   :  10-15 குன்நி஦பவு (1.3-2g) 
 அனுதோணம்   :  சர்க்கவ஧,த஡ன்,ப஢ய் 
 ஡பீேம்த஢ோய்கள்  :  த஥க஬ி஦ோ஡ிகள்,ப௄த்஡ி஧கிரிச்ச஧ம்,குட்டம், 
஬ோ஡ம். 
 
6.஡ிப்தினி இ஧சோ஦஠ம் 
 
 அபவு   :  ப஬பேகடி஦பவு 
 அனுதோணம்   :  ஡ோம்தி஧ச்பசந்தூ஧ம் 
 ஡பீேம்த஢ோய்கள்  :  தசத்து஥ம் 96, இவபப்பு, ச஦ம்,கோசம். 
 
7.தி஧஥ி ப஢ய்  
 
 அபவு   :  1\4 – 1\2 தனம்(8-16mg) 
 ஡பீேம்த஢ோய்கள்  :  தித்஡ோ஡ிக்கம், சூ஡கசன்ணி 
 
8.஢ீர்ப௃ள்பிகுடி஢ீர் 
 
 அபவு   :  1\2 ஆ஫ோக்கு(84ml),2 த஬வப 
 ஡பீேம்த஢ோய்கள்  :  தசோவத, ஢ீர்க்கட்டு 
 
9.஥ண்டூ஧ோ஡ி குடி஢ீர் 
 
 அபவு   :  1\4 ஆ஫ோக்கு(42ml),2 த஬வப 
 ஡பீேம்த஢ோய்கள்  :  தோண்டு,தசோவத,கோ஥ோவன,஥தகோ஡஧ம். 
 
10.ப஢ல்னிக்கோய் இபகம்30 
 
 அபவு   :  புன்வணக்கோ஦பவு 
 ஡பீேம்த஢ோய்கள் : தோண்டு,கோ஥ோவன,அ஫ற்சி,஬நட்சி,஡ி஥ிர்஬ோப௅, 
     குன்஥ம்,உடம்பதரிவு. 
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NELLIKAI (Phyllanthusemblica) 
DESCRIPTION: 
              Emblica is a small to medium-sized deciduous tree native to tropical southeastern 
Asia. Its leaves are simple, feather-like, and closely set along the branchlets. Flowers are 
green-yellow, and the round, greenish-yellow fruits are smooth and hard in appearance. The 
fruits, which ripen in autumn and are harvested by hand, are commonly used in the Indian 
diet. 
SYNONYMS 
Eng  :  Indian gooseberry  
Mal  :  Nellikay 
Sans  :  Amalaki 
Hind  :  Amlika 
 
TAXONOMICAL CLASSIFICATION:   
Kingdom : Plantae 
Clade  : Angiosperms  
Order  : Malpighiales 
Family  : Phyllanthaceae 
Genus  : Phyllanthus  
Species : Emblica 
 
PART USED:  Whole plant 
 
CHEMICAL CONSTITUENT: 
              The fruit is rich in Vit-C (70-72%) and phyletic acid, gallic acid, lipid, flavonoids, 
colloidal complexes and micric acid. 
 The fruit pulp contain:  moisture- 81.2, protein – 0.5, fat – 0.1, mineral matter – 0.7, fiber – 
3.4, carbohydrate – 14.1, Ca- 0.05, P – 0.02%, Fe – 1.2/100g, nicotinic acid – 0.2mg/ 1.00g, 
vitamin C – 600 mg/ 100g.The fruit is rich source of pectin.31 
ACTION: 
 The plant has Astringent, Refrigerant, Laxative, and Diuretic actions. 
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USES: 
 Amla fruit is probably the richest known natural source of vitamin C. The fruit juice 
contains nearly 20 times as much vitamin C as orange juice. 
 
 The fruit is used successfully in the treatment of human scurvy. 
 
 Dried fruit is useful in haemorrhage, diarrhoea and dysentry. 
 
 In combination with iron it is used as a remedy for anaemia, jaundice and 
dyspepsia.
11 
 
 Fermented liquor prepared from the fruit is used in jaundice, dyspepsia and cough. 
 
 Acute biliary dysentry may be arrested by drinking a sherbet of amla with lime juice. 
 
 The seeds are used in the treatment of asthma, bronchitis. 
 
 The fruit is used in the preparation of writing inks and hair dyes.  
 
 The fixed oil extracted from the fruits is reported to have the property of promoting 
hair growth. 
 
 The fruit also used as an external application for inflammation of the eyes.28 
 
Scientific validation:  
Toxicity study: 
This article reveals the safety of the amla.In toxicity studies in rats no toxicity was 
observed in single and longer-term–dose administration. Additionally no detrimental effect 
was noted on the liver or renal function
32
. No chromosomal aberrations were found 
following 7- and 14-day treatment regimens in rats with crude fruit extract
33
.In another 
experiment no toxicity or mutagenicity was observed in rats even at the highest doses.
34
 
Antioxidant activity: 
This article showed the antioxidant property of the amla.Which has a rich source of 
vitamin C is considered to be effective in slowing down the ageing process. Ageing is a 
cumulative result of damage to various cells and tissues mainly by oxygen free radicals. 
Vitamin C is a scavenger of free radicals which breaks them down; it has an antioxidant 
synergism with vitamin E which prevents pre-oxidation of lipids. 
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 Many papers are published about the magical effects of amla. However little is 
known about the chemistry and biological activity of its major constituents hydrolysable 
tannins (10-12 % in pericarp) except that they contained gallic acid and ellagic acids that 
inhibit the degradation of vitamin C and had some pharmacological activity entirely 
unrelated to the clinical use of fruits.
35 
A herbo-mineral formulation of the Ayurveda medicine named Peptic are composed 
of Emblica officinalis, Glycyrrhiza glabra and Tinosporacordifolia was tested for its anti-
ulcer anti-oxidant activity in rats. Reports were made that Pepticare exhibit antiulcer activity 
which can be attributed to its anti-oxidant property.
36
 
Immunomodulatorproperty: 
         This article exposed the immunomodulatory effect of amla.Immu-21 is an Ayurvedic 
polyherbal formulation containing extracts of Emblica Officinalis, Ocimum sanctum, 
Withania somnifera and Tinospora cordifolia. Its immune modulatory activity was studied 
on the proliferative response of splenic leukocytes to T cell mitogens, concanavalin (Con)-A 
and phytohemagglutinin (PHA) and B cell mitogen, lipopolysaccharide (LPS) in vitro by 
[3H]-thymidine uptake assay in mice. Pretreatment with Immu-21 selectively elevated the 
proliferation of splenic leukocyte to B cell mitogen LPS and cytotoxic activity against K 
562 cells in mice.
37 
Hypolipidemic effect: 
          This article offered the hypolipidemic effect of amla.Flavonoids derived from 
E.officinalis exhibit maximum beneficial action by eliciting highly potent hypolipidaemic 
and hypoglycemic activities. In addition to this flavonoids were found to be effective in 
elevating the haemoglobin levels in rats
38
. It is also reported to be as antitumor
39
. 
Triphala containing one of the ingredients as E.officinalis is used to treat diseases such as 
anaemia, fever, chronic ulcers, constipation, jaundice and asthma. Polyphenolic fractions 
isolated from Triphala exhibit antimutagenic effect
40
. Active principles of Triphala was 
further evaluated and used as an excellent therapeutic formulation for infected wounds
41
. 
In Skin Sores and Wounds: 
  This paper reveals the productive effect of amla in skin.The milky juice of the leaves is a 
good application to sores. Grind the bark of E.officinalis (10g) into a paste and apply to the 
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cut or wound area once daily for 2 to 3days. Alternatively squeeze the leaves and extracts 
the juice to the cut once daily for 3 to 4 days. Healing occurs when the dynamic harmony of 
the doshas is restored
42
. 
In Dental disease: 
This article deals with the detal care of the amla root.The roots (10 g) are ground and taken 
twice daily for one day only after taking food. Alternatively the leaves of are squeezed and 
the juice extracted. This juice is put in the ear (a few drops) to find relief from toothache.
43
 
In Hair Growth: 
This paper showed amla uses in hairgrowth.It boosts absorption of calcium thus 
creating healthier bones, teeth, nails and hair. It also helps maintain youthful hair colour and 
retards premature greying and supports the strength of the hair follicles so there is less 
thinning with age 55. The crushed fruits have a good effect on hair growth and prevent hair 
greying.
44 
In Ophthalmic Disorder: 
This article deals with the purpose of amla in eye related diseases.The clinical trial 
was conducted in patients suffering from different ophthalmic disorders namely 
conjunctival xerosis, conjunctivitis, acute dacryocystitis, degenerative conditions and 
postoperative cataract patients with a herbal eye drop preparation. In most cases the 
improvement was observed with the treatment of the herbal eye drop. 
During the course of study no side effects were observed and the eye drop was well 
tolerated by the patients. Ophtha care exhibit beneficial role in a number of inflammatory, 
infective and degenerative ophthalmic disorders.
45 
In Skin cancer: 
The cancer preventive effect of E.officinalis was investigated on a two-stage process of skin 
cancer induced by7, 12dimethylbenz (a) anthracene (DMBA)in Swiss albino mice. It 
showed significant chemo-preventive effects on DMBA initiated and croton oil (1% in 
100μl of acetone)promoted skin cancer development. P. emblica exhibited a significant 
reduction in tumour incidence, tumour yield, tumour burden and a cumulative number of 
papillomas. These findings were indicative of the chemopreventive potential 
ofE.officinalisagainst skin carcinogenesis
46
. 
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In Diabetes: 
 This paer showed the amla uses in diabetic patiants.Oral administration of the 
extracts (100 mg/kg body weight) reduced the blood sugar level in normal and in alloxan 
(120 mg/kg) diabetic rats significantly within 4 hours. Emblica officinalis and an enriched 
fraction of its tannoids are effective in delaying development of diabetic cataract in rats
47
. 
Aldose reductase (AR) has its involvement in the development of secondary complications 
of diabetes including cataract. Emblica Officinalis is proved as an important inhibitor of 
AR. Exploring the therapeutic value of natural ingredients that people can incorporate into 
everyday life may be an effective approach in the management of diabetic complications
48
. 
It decreases the fasting and 2-hour postprandial serum glucose level. It was demonstrated in 
a clinical study using both healthy and type 2 diabetic volunteers. One to 3 g of powdered 
dried fruit was consumed daily in 30 mL of water for 21days.
49 
26 
 
3.3.கீழ்க்கோய்ப஢ல்னி 
த஬றுபத஦ர்: 
கீழ்஬ோய்ப஢ல்னி 
கீ஫ோப஢ல்னி 
஥ோனறுது 
஥ோனிணி 
பதபேபுத்஡ி஧ோ 
        தூதோனோபூ஡ோத்஡ிரி 
        பதபே஬ிரி஦கோ50 
 
த஦ன்தடும் உறுப்பு :  சப௃னம் 
சுவ஬  :  து஬ர்ப்பு,வகப்பு,புபிப்பு,இணிப்பு 
஡ன்வ஥ :  ஡ட்தம் 
திரிவு  :  இணிப்பு 
 
பசய்வக:   
 ஬கீ்கப௃பேக்கி  -  Deobstruent  
சிறு஢ீர்ப்பதபேக்கி  -  Diuretic 
        து஬ர்ப்தி   -  Astringent 
குபிர்ச்சிப௅ண்டோக்கி -  Coolent28 
கு஠ம்: 
 “ச஡ீ஥஡ி தித்஡஬ினடஞ்  பசவ்஬ி஫ி஦ின் தணோய்க் கூட்டம் 
  பூ஡ப஥ோடு தத஦ி஧த்஡ப் ததோக்குகல௃ம் – பூ஡னத்துள் 
  ஡ோழ்஬ோய்ப் த஠ிந்த஡குந் ஡ப்தோது பதோய்஦னத஬  
 கீழ்஬ோ ப஦னுப஢ல்னிக் தக”. (அ.கு) 
  
இ஡ணோல் அசுத்஡ ஧த்஡ம், ஬ி஫ித஢ோய், ஢ோ஬நட்சி, ஡ோதம் இவ஬கவபப௅ம் 
஢ீக்கும்.஬ோ஡த்வ஡ப் பதபேக்கும். 
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஬஫க்குப௃வந: 
 
 தன தி஠ிகபிணோல் ப஢ோந்து உடல் ப஥னிந்து 
ப஬ல௃த்஡ிபேக்குங்கோல்,கீ஫ோப஢ல்னிவ஦ அவ஧த்து , ஢ல்ன தசு஬ின் ஡஦ிரில் 
கனந்து, ஢ோல௃ம் கற்தப௃வந஦ின்தடி உண்஠ ,த஥கப஬ட்வட ப௃஡னி஦ த஢ோய்கள் 
஦ோவும் ததோம். 
 
 இப்பூண்டின் இவன பகோழுந்வ஡க் குடி஢ீரிட்டுச் ச஡ீக஫ிச்சலுக்குக் 
பகோடுக்கனோம். 
 
 கற்கம் : இ஡ன் சப௄னத்வ஡ அவ஧த்து எபே பகோட்வடப் தோக்குப் தி஧஥ோ஠ம் 
தசு஬ின் தோனில் கனக்கி சோப்திட்டு ஬஧ தசோவக , கோ஥ோவன, தோண்டு, ஬ோ஡தித்஡ 
த஧ோகங்கள் கு஠஥ோகும். 
 
 இ஧த்஡ம் அ஡ிகப்தடும், கண் குபிபேம். 
 
 த஬வ஧ கழு஢ீரில் அவ஧த்துக் கனக்கி சோப்திட பதபேம்தோடு ததோம். 
 
 த஬வ஧ப் தச்வச஦ோய் 17 கி஧ோம் ஋டுத்து அவ஧த்து தோனில் கனக்கிக் பகோடுக்க 
கோ஥ோவன ததோம். 
 
 இவன , த஬ர் இ஧ண்வடப௅ம் குடி஢ீரிட்டுச் சு஧ங்கல௃க்குச் சூட்தடோதட பகோடுக்க 
கோய்ச்சல் ஡஠ிப௅ம்.28 
 
கீ஫ோப஢ல்னி தசர்ந்஡ திந஥பேந்துகள்: 
 
1.தஞ்சகவ்஬ி஦ தனகி஦ம்9 
 
 அபவு   :  ப஢ல்னிக்கோ஦பவு 
 ஡பீேம்த஢ோய்கள்  :  ஡஧ீோ஡பதபேம்தோடு,சூ஡க஬னி,குன்஥ம். 
 
2.஡ிப்தினிகிபே஡ம் 
 
 அபவு   :  1-2 த஡க்க஧ண்டி  
 ஡பீேம்த஢ோய்கள்  :  சு஧ம்,஬ிக்கல்,அத஧ோகம்,஡வனத஢ோய். 
 
3.இ஧ோஜசிந்஡ோ஥஠ி ஋ண்ப஠ய் 
 
 அபவு   :  1\4 – 1\2 தனம்(8-16ml)  
 ஡பீேம்த஢ோய்கள்  :  வககோல்திடிப்பு,கி஧ந்஡ி,பகோறுக்கு. 
 
4.஬பே஠தனோக பசந்தூ஧ம்10 
 
 அபவு   :  1\4- 11\2 குன்நி(32.5-195mg)  
அனுதோணம்   :  த஡ன்,ப஢ய் 
 ஡பீேம்த஢ோய்கள்  :  தோண்டு,கோ஥ோவன. 
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5. கரிசோவன இபகம்29 
 
 அபவு   :  புன்வண஦பவு 
 ஡பீேம்த஢ோய்கள்  :  தோண்டு,தித்஡ப஬ட்வட,஋ரிவு,கி஧ோ஠ி 
 
6.ஆடோப஡ோவட ப஢ய் 
 
 அபவு   :  கோபசவட(165mg) 
 ஡பீேம்த஢ோய்கள்  :  ஢ோட்தட்டசு஧ம். 
 
7.ப஢ோச்சி வ஡னம் 
 
 அபவு   :  கோசபவு(165mg) 
 ஡பீேம்த஢ோய்கள்  :  5 ஬வக கோசம்,க஦ம். 
 
8. தஞ்சபகௌ஬ி஦க்கிபே஡ம்10 
 
 அபவு   :  1-2 த஡க்க஧ண்டி 
 ஡பீேம்த஢ோய்கள் : பதபேம்தோடு,குன்஥ம்,தீ஢ிசம்,தித்஡ப்தோண்டு, 
     கோ஥ோவன. 
9.கீ஫ோப஢ல்னி வ஡னம் 28 
 
 தி஧த஦ோகம்   :  ஸ்஢ோணம் பசய்஦ 
 ஡பீேம்த஢ோய்கள்  :  உட்சு஧ம்,அ஫வன,வக ,கோல், கண்  
     ஋ரிச்சல்,஢டுக்கல்,஡வனசு஫ற்நல், ஬ோந்஡ி. 
10.கீ஫ோப஢ல்னி கற்கம் 
 
 அபவு   :  பகோட்வடப்தோக்கபவு 
 அனுதோணம்   :  தசும்தோல் 
 ஡பீேம்த஢ோய்கள்  :  கோ஥ோவன,தசோவத,தோண்டு, 
஬ோ஡தித்஡த஧ோகங்கள். 
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KEEZHANELLI (Phyllanthus niruri) 
DESCRIPTION: 
 It grows 50 – 70 cm tall and bears ascending herbaceous branches. The bark is 
smooth and light green. It bears numerous pale green flowers which are often flushed with 
red. The fruits are tiny, smooth capsules containing seeds. 
SYNONYMS 
Eng : Indian Phyllanthus  
Mal : Keezhanelli  
Sans : Bhumyamalaki 
Hind : Bhutan-anvalah 
 
TAXONOMICAL CLASSIFICATION:   
Kingdom : Plantae 
Clade  : Angiosperms  
Order  : Malpighiales  
Family  : Phyllanthaceae 
Genus  : Phyllanthus  
Species : Niruri / amarus 
 
PARTS USED:Whole plant  
CHEMICAL CONSTITUENTS:  
Phyllanthin, hypophyllanthin, phyllanthus D, geranin, rutin, corilagin, linnanthin, 
amarulone, epibubbialine and isobubbialine. 
In leaf contain :  moister content 9.00 – 9.10%, protein 18.77 – 19.00%, 
carbohydrate – 56.97 – 57.02%, fiber 9.13 – 9.29%, Fe 7.57 – 7.89, Zn 0.27 – 0.30, Mg 
40.00 – 45.0,Ca 178.33 – 182.10, ascorbic acid 18.80 – 19.12mg/100g.K 45.00 – 
50.10mg/100g.
51 
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ACTION: 
        The plant has Deobstruent, Diuretic, Astringent, Coolent actions. 
 
 USES: 
 It is used in stomach troubles such as dyspepsia, colic, diarrhoea and dysentry and 
also employed in dropsy and diseases of the urinogenital system. 
 
 Fresh roots are said to be beneficial for jaundice. They are taken with milk as a 
galactagogue. 
 
 A decoction of the leaves is used as a refrigerant for the scalp. 
 
 Leaves and roots are made into the poultice with rice water for application on 
oedematous swellings and ulcers. 
 
 The latex is also applied to offensive sores and ulcers and mixed with oil it is used in 
ophthalmia. 
 
 It helps to remedy for fatty liver and liver damage due to any reason. It promotes 
liver action. 
 
 It is also said to be used in the case of anorexia.11 
 
 The infusion of the root and leaves is a good tonic and diuretic when taken cold in 
repeated doses. 
 
 A poultice of the leaves with salt cures scabby disorder of the skin. 
 
 Infusion of young shoots is an effective cure to treat dysentery. 
 
 Fresh juice of the whole plant along with clarified butter is very effective in the 
treatment of menorrhagia, leucorrhea and gonorrhoea. 
 
 The plant said to be used in diabetes.  
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Scientific validation: 
Toxicological assessment: 
This article reveals the safety of P. amarus. There was no mortality among the 
animals and they did not show any toxicity or behavioural changes at the dose level of 2000 
mg/kg. These findings suggest that Phyllanthus amarus was safe and non-toxic to rats up to 
2000 mg/kg in acute toxicity study.
52 
Antiviral activity:  
This paper deals the antiviral property of Keezhanelli.The aqueous extract of P. 
amarus was tested for its activity against WSSV in marine shrimp and freshwater crabs. 
P.amarus showed antiviral activity against WSSV at the concentration of 150 mg/kg of 
animal body weight.
53 
 An aqueous extract on human hepatocellular carcinoma derived cell at1 mg/ml 
concentration on a single dose. Inhibition of secretion of HBsAg for a period of 48 h was 
observed.
54
 
Immunomodulator effect:  
           This article shows the immunomadulatory effect of P. niruri.Thirty-two male Wistar 
rats of average body weight of 85.5 ± 4.55 g were grouped into four (AD). Group A 
received distilled water (control) while doses of 250, 500 and 1000 mg/kg body weight of 
extract were orally administered once daily for 84 days to animals in groups B, C and D 
respectively. The result shows reduce the body weight and blood glucose level at the same 
time it increases the serum interleukin-6 and tumour necrosis factor-αconcentrations 
reduced and the lipid profile level was reduced and the WBC count was increased. The 
result of the study established scientifically the folklore use of the aqueous leaf extract of P. 
amarus as blood tonic for the prevention and or cure of infective and degenerative 
diseases.
55
 
Antiamnesic effect:   
This article showed the antiamnesic effect of Keezhanelli.Phyllanthus amarus (PAs) 
50, 100 and 200 mg/kg produced a dose-dependent improvement in memory scores of 
young and older mice. PAs also reversed successfully the amnesia induced by scopolamine 
(0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.). The brain cholinesterase activity was also 
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reduced. The underlying mechanism of action for the observed nootropic effect may be 
attributed to pro-cholinergic activity exhibited by PAs.
56
 
Hepatoprotective activity:  
This paer reveals the hepatoproductive activity of P. amarus.In-vivo methanolic and 
aqueous extracts of the seeds of P. amarus 250mg/kg were found to have protective 
properties in rats with CCl4 induced liver damage as judged from serum biochemical 
enzyme marker activities and histopathological studies.P. amarus (1–4 mg/ml) shows the 
beneficial roles against ethanol-induced liver injury in rats. The possible mechanism may 
involve their antioxidant activity.
57 
Antimicrobial activity: 
          This paper explain the antimicrobial effect of Phyllanthus.The strains isolated from 
both HIV seropositive patients were susceptible to various concentrations of the P. amarus 
extracts (5, 10, 20, 40 and 80 mg ml-1) which were assessed against extend spectrum β-
lactamase producing Escherichia coli isolated from the stool samples of HIV seropositive 
patients with or without diarrhoea.
58
 
Hypolipidemic effect:  
    This paper deals the hypolipidemic property of Keezhanelli.Hydro-alcoholic extract 
of leaves of Phyllanthus amarus Schumacher (HAEPAS) was studied for its invivo anti-
hyperlipidemic potential using cholesterol diet-induced hyperlipidemia model in rats. The 
result of the study indicated that HAEPAS possess significant hypolipidemic activity at 
doses 300 and 500 mg/kg.
59
 
Antioxidant property: 
          This article showed the antioxidant acitivityof the Phyllanthus.The aqueous extract 
(PAAEt) treated rats showed a significant decrease in plasma LPO and a significant increase 
in plasma vitamin C, uric acid, GSH levels and GPx, CAT and SOD activities. Single cell 
gel electrophoresis experiment reveals that PAAEt was devoid of genotoxicity and had a 
significant protective effect against H2O2, STZ and nitric oxide (NO) induced lymphocyte 
DNA damage.
60
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Hypotensive effect:  
This paper establishes the hypotensive effect of Keezhanelli.The effect of the 
aqueous extract of the leaves of P. amarus on blood pressure was evaluated in normotensive 
male rabbits. Intravenously administered aqueous doses (5 mg to 80 mg/kg) of the extract to 
anaesthetized normotensive male rabbits produced a significant fall in mean diastolic, 
systolic and mean arterial pressures in a graded dose-response manner. The dose of 5 mg/kg 
produced the least hypotensive effect causing a fall in mean diastolic, systolic and mean 
arterial pressure of 13.3 ± 3.1, 19.7 ± 5.4 and14.3 ± 3.4 mmHg respectively  while the dose 
of 80 mg/kg produced the greatest fall in mean diastolic, systolic and mean arterial pressure 
of 49.7 ± 7.9, 45.5 ± 9.5 and 48.00 ± 6.5 mmHg respectively. 
61
 
Antispasmodic effect: 
           This paper show the muscular function of the Keezhanelli.The ether extract obtained 
from P. niruri was found to be the most active as an antispasmodic being about 6- to 27-
fold more effective in causing antispasmodic actions in vascular and nonvascular 
preparations than other extracts.
62
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3.4. கரிசனோங்கண்஠ி 
த஬றுபத஦ர்: 
 
கரிசணோங்கண்஠ி, 
கரிசோவன, 
கரி஦சோவன, 
வகதகசி, 
வக஬சீி இவன,  
வக஦ோந்஡கவ஧, 
திபேங்க஧ோஜம், 
கரிப்தோன், 
வக஦ோன், 
த஡க஧ோஜம். 
 
஬வக   : ஢ீனம், ஥ஞ்சள், சிகப்பு, ப஬ள்வப 
த஦ன்தடும் உறுப்பு :   பூண்டு 
சுவ஬   :   வகப்பு 
஡ன்வ஥  :   ப஬ப்தம் 
திரிவு   :  கோர்ப்பு 
 
பசய்வக:   
தித்஡஢ீர்ப்பதபேக்கி -  Cholagogue  
உ஧஥ோக்கி   -  Tonic 
உடற்த஡ற்நி  -    Alterative 
஬ோந்஡ிப௅ண்டோக்கி  -  Emetic 
஢ீர்஥னம்ததோக்கி  -    Purgative 
஬கீ்கப௃பேக்கி  -  Deobstruent   
ஈ஧ல்த஡ற்நி   -    Hepictonic  
 
கு஠ம்:  
“கு஧ற்கம்஥ற் கோ஥ோவன குட்டப஥ோடு தசோவத 
        ப௅நற்தோண்டு தன்தணோ ப஦ோ஫ி஦- ஢ி஧ற்பசோன்ண 
        ப஥ய்஦ோந் ஡கவ஧ப஦ோத்஡ ஥ீபி ண்ட௃ ஢ற்புனத்துக் 
வக஦ோந் ஡கவ஧ப஦ோத்஡க் கோல்”. (அ.கு) 
 
இ஡ணோல் கு஧லுறுப்பு த஢ோய், கோ஥ோவன, குட்டம், ஬கீ்கம், தோண்டு, தல்த஢ோய் ஆகி஦வ஬ 
ததோம்.உடலுக்கு பதோற்சோ஦லும், தனப௃ம் உண்டோகும்28. 
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஬஫க்குப௃வந:  
 
 கரிசவனச் சூ஧஠த்வ஡ அ஦ச்பசந்தூ஧த்஡ிற்கு அனுதோண஥ோகக் பகோள்ப 
தோண்டு,தசோவத,கோ஥ோவன ப௃஡னி஦ த஢ோய்கள் ஡பீேம். 
 
 த஬ர்ப்பதோடித்஡வ஡, கல்லீ஧ல் ஥ண்஠஧ீல் த஢ோய்கல௃க்கும், த஡ோவனப் தற்நி஦ 
தி஠ிகல௃க்கும் பகோடுக்கனோம். 
 
 ஥ஞ்சள் கரிசவன கநி஦ோகச் பசய்துண்஠ அநி஬ின் ப஡பிவும் ஡ிபேவும் தசபேம். 
 
 இவனச்சோற்வந ஢ல்பனண்ப஠ய் அல்னது த஡ங்கோய் ஋ண்ப஠஦ில் கோய்ச்சித் 
஡வனக்குத் த஡ய்த்து ஬஧ ப௃டிகறுத்துத் ஡வ஫த்து ஬பபேம்28. 
 
 கரிசோவன இவனவ஦ சிநிது ஥ிபகுடன் கூட்டி அவ஧த்து ஡ிணப௃ம் இபே த஬வப 
சுண்வடக்கோய் தி஧஥ோ஠ம் சோப்திடதோண்டு, தசோவத, கோ஥ோவன ப௃஡னி஦ 
த஢ோய்கள் ஡பீேம். 
 
 கரிசோவனச் சோற்வந என்று அல்னது இ஧ண்டு த஡க்க஧ண்டி ஬஡ீம் த஥ோரில் 
கனக்கி சோப்திடனோம்63. 
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கரிசோவன தசர்ந்஡ திந஥பேந்துகள் 
 
 1.தஜோ஡ி஧ச ஥ோத்஡ிவ஧9 
 
 அபவு   :  7-8 ஥ோத்஡ிவ஧ 
 அனுதோணம்   : சுக்குகி஦ோ஫ம் 
 ஡பீேம்த஢ோய்கள்  :  ஥னசனக்கட்வட உவடக்கும் 
 
2.அஷ்டவத஧஬஥ோத்஡ிவ஧  
 
 அபவு   :  1 ஥ோத்஡ிவ஧ ( 2 த஬வப, 2 ஢ோள்)  
அனுதோணம்   :  ப௃வனப்தோல்,த஡ன் 
 ஡பீேம்த஢ோய்கள்  :  சு஧ம், சந்஢ி, த஡ோ஭ம்,இசிவு 
 
3. ஋஥஡ண்டக்கபிவக  
 
 அபவு   :  1 ஥ோத்஡ிவ஧   
அனுதோணம்   :  த஡ன் 
 ஡பீேம்த஢ோய்கள்  :  சு஧ம், சன்ணி, த஡ோ஭ம் 
 
4. ஡ிப்தினிதனகி஦ம் 
 
 அபவு   :  சுண்வடக்கோய் தி஧஥ோ஠ம் 
 ஡பீேம்த஢ோய்கள்  :  ஈவப,இபே஥ல்,கோசம்,அத஧ோகம்,க்ஷ஦ம் 
 
5.இஞ்சிதனகி஦ம்  
 
 அபவு   :  க஫ற்சிதி஧஥ோ஠ம்  
 ஡பீேம்த஢ோய்கள்  :  ஌ப்தம்,ப஢ஞ்பசரிவு,஬ோய்கு஥ட்டல். 
 
6.கூழ்தோண்டகிபே஡ம் 
 
 அபவு   :  2-3 த஡க்க஧ண்டி 
 ஡பீேம்த஢ோய்கள்  :  தி஧த஥கம்,கிரிச்சு஧ம்,த஡க஋ரிவு,஬நட்சி. 
 
7.பதோன்ணோங்கண்஠ி வ஡னம் 
 
 அபவு   :  2-3 த஡க்க஧ண்டி  
 ஡பீேம்த஢ோய்கள்  :  ப஬ட்வட, ப௄னம், தி஧த஥கம்,த஥ககோங்வக. 
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8.஥ோந்஡ ஋ண்ப஠ய் 
 
 அபவு   :  2-3 த஡க்க஧ண்டி  
அனுதோணம்   :  ப௃வனப்தோல் 
 ஡பீேம்த஢ோய்கள்  :  சகன஥ோந்஡ப௃ம் ஡பீேம். 
 
9. கபேடன்கி஫ங்கு ஋ண்ப஠ய் 
 
  அபவு   :  1\4 – 1\2 அவுன்ஸ் 
 ஡பீேம்த஢ோய்கள்  :  த஥கம்21,தவட,஬ோப௅,த஥க஧஠ம்,பசோநி, சி஧ங்கு. 
 
10.அ஦ச்பசந்தூ஧ம் 
 
 அபவு   :  குன்நிப஦வட(130mg)  
அனுதோணம்   :  ப஢ய்,த஡ன் 
 ஡பீேம்த஢ோய்கள்  :  தோண்டு, தசோவத, கோ஥ோவன10 
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KARISALAI (Ecliptaalba) 
DESCRIPTION: 
          Eclipta alba (Asteraceae) is an annual herbaceous plant commonly known as a false 
daisy. It is an erect or prostrates much branched roughly hairy annual rooting at the nodes; 
the leaves are opposite, sessile and lanceolate. It is also known as Bhringaraj and 
Karisilakanni which is found a common weed throughout India ascending up to 6000 ft. The 
genus name comes from the Greek word meaning “Deficient” with reference to the absence 
of the bristles and awns on the fruits. The specific Eclipta alba means white which refers to 
the colour of the flowers. 
SYNONYM: 
Eng :  Trailing eclipta 
Mal :  Tanjung 
Sans :  Bhringaraj  
Hind :  Bungah 
TAXONOMICAL CLASSIFICATION:   
Kingdom :  Plantae 
Clades  : Angiosperms  
Order  :  Asterales 
Family  :  Asteraceae 
Genus  :  Eclipta  
Species :  Alba 
 
PART USED: Whole plant 
28
 
CHEMICAL CONSTITUENT: 
It contains alkaloids, flavonoids, stigmasterol, triterpenoids, glucosides, wedelolactone, 
demethylwedelolactone and dimethyl wedelolactone 7 glycosides. 
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ACTION: 
            The plant has Cholagogue, Tonic, Alternative, Purgative, Deobstruent, Hepatotonic 
action.
64` 
MINERAL ELEMENTS:  
    The minerals Na, Mg, Al, K, Ca, Fe, Cr, Mn, Co, Ni, Cu, Zn and Ag were detected in the 
plant. The voltammetric analysis carried out on leaves showed that the concentrations of 
macronutrients such as Ca, P, Mg, K, Fe and S ranged from 9.62-41.74, 1.00-8.630, 3.53-
35.50, 12.04-56.28, 0.111-3.845 g/kg and 1.124-5.843 mg/kg.
11 
USES: 
 The plant is used in indigestion, diarrhoea, dysentry, and digestive diseases. 
 
 Roots and leaves are largely used alone or in combination with ajowan seeds in 
derangement of the liver and gallbladder. 
 
 It is used as a liver tonic. 
 
 It is highly effective for a urinary tract infection. 
 
 Leaves are very effective for skin disorders, skin allergies and cracked heels. 
 
 It helps in rejuvenate the body. 
 
 Leave extract is also used for a toothache. 
 
 It increases the learning and memory ability.  
 
 It is used in hair dyes and for tattooing purpose. 
 
 It is very effective for eyesight and helps to the purification of blood. 
 
 It promotes hair growth and prevents hair fall, premature greying. 
 
 Leaves are used for eczema, ringworm and leucoderma.11 
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Scientific validation: 
Toxicity studies: 
In studies conducted the alcoholic extract of E.alba shows no signs of toxicity in rats 
and mice and the minimum lethal dose was found to be greater than 2.0g/kg when given 
orally and intraperitoneally in mice
65
.   
Hepatoproductive activity: 
         This review deals the hepatoproductive effect of alba.The hepatoprotective effect of 
the ethanol/water (1:1) extract of Eclipta alba has been studied at subcellular levels in rats 
against CCl4-induced hepatotoxicity. E.alba significantly counteracted CCl4-induced 
inhibition of the hepatic microsomal drug metabolizing enzymes. The loss of hepatic 
lysosomal acid phosphatase and alkaline phosphatase by CCl4 was significantly restored by 
E.alba. The study shows that hepatoprotective activity of Eclipta alba is by regulating the 
levels of hepatic microsomal drug metabolizing enzymes.
66
 
Antihyperlipidemic properties: 
         This paper deals the antihyperlipidemic action on E. alba.It has been reported that in 
the atherogenic diet-induced hyperlipidemic model the aqueous leaf extract of the Eclipta 
prostrata was given orally to the rats which significantly reduced total cholesterol, 
triglycerides, total protein. There was a significant elevation in the high-density lipoprotein 
cholesterol levels. 200mg/kg of extract showed better results compared to 100mg/kg.
67
 
Immunomodulatory activities: 
          This review point out the immunomodulatory activity ofE.alba.Experimentation 
made to assess the immunomodulatory activity of methanol extracts of whole plant of E. 
alba (1.6% wedelolactone) at five dose levels (dose-response relationship) ranging from 
100 to 500 mg/kg using carbon clearance, antibody titer and cyclophosphamide 
immunosuppression parameters significantly increased phagocytic index and antibody titer 
and the F ratios of the phagocytic index and WBC count were also significant.
68
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Anti-inflammatory activity:   
         These papers describe the anti inflammatory effect of E. alba. Wistar albino rats were 
used to investigate anti-inflammatory activity in which methanolic extract was administered 
orally. 100 and 200 mg/kg showed significant anti-inflammatory activity in carrageenin and 
egg white induced hind paw oedema in rats which were compared with indomethacin (10 
mg/kg) and cyproheptadine (8 mg/kg).
69 
Analgesic activity: 
This article show the analgesic effect of E. alba.Analgesic effect was studied on 
albino mice using an ethanolic and alkaloidal extract of Eclipta alba. Standard experimental 
models such as the tail clip method, the tail flick method and the acetic acid-induced 
writhing response were used which showed both the ethanol extract as well as the total 
alkaloids produced good analgesic activity in all the different models of analgesia used. The 
total alkaloidal fraction was the most efficacious in all models tested.
70 
Antidiabetic activity:  
           This review reveal the antidiabetic activity of E. alba.Leaf suspension (2 & 4g/kg) 
orally in alloxan-induced diabetic rats resulted in a reduction in blood glucose level, 
glycosylated haemoglobin. There was the decreased activity of glucose-6 phosphatase and 
fructose1, 6-bisphosphatase, and an increase in the activity of liver hexokinase. Thus oral 
administration of Eclipta alba suspension possesses potent antihyperglycemic activity.
71
 
Hair growth: 
         This paper show the uses of E. alba in hairgrowth.It is used in hair oil preparations 
since it promotes hair growth and maintains hair black. 10%w/v of Eclipta alba was the 
main ingredient in the preparation of a herbal formulation for hair growth.
72 
Anticancer activity: 
          This review deals the anticancer property of the E. alba.Dasyscyphin-C (saponins) a 
newer isolated compound from E.prostrata reported having anticancer-cytotoxic activity. It 
was tested under in-vitro conditions in HeLa (Human cervical carcinoma) & Vero cell lines. 
At the concentration of 50µg/ml, it showed a good anticancer-cytotoxic activity on HeLa 
cells.
73
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3.5.த஡ன் 
பசய்வக: 
   உள்ப஫னோற்நி, 
  ஥ன஥ிபக்கி,  
து஬ர்ப்தி,  
அழுகனகற்நி, 
தகோவ஫஦கற்நி,  
ததோ஭஠கோரி, 
தசித்஡தீூண்டி, 
தூக்கப௃ண்டோக்கி. 
 
த஡ணில் உடலுக்கு த஡வ஬஦ோண இணிப்புச் சத்து, உதனோகசத்துகள், வ஬ட்ட஥ின் 
ததோன்ந ஋ல்னோச்சத்துகல௃ம் சிறு அப஬ில் பதோபேந்஡ி஦ிபேப்த஡ோகத் ஡ற்கோன 
஬ிஞ்ஞோணிகள் கண்டுதிடித்஡ிபேக்கின்நோகள். 
 
஢ம் நூற்கபில் த஡ன் 12 ஢ோ஫ிவக஦ில் ஜி஧஠஥ோகி஬ிடுகின்நப஡ன்று கூநப்தட்டுள்பது. 
 
஬஫க்குப௃வந: 
 
 இதனகி஦ம், தோ஠ி஡ம், ப஥ழுகு, கட்டு, கண் வ஥ ததோன்ந ஥பேந்துகள் பசய்஦த் 
த஡ன் த஦ன்தடுகிநது. 
 
 தற்தம்,பசந்தூ஧ம்,சூ஧஠ம், ஥ோத்஡ிவ஧, குடி஢ீர் ததோன்நவ஬கல௃க்கு சிநந்஡ 
துவ஠஥பேந்஡ோகும். 
 
 கு஫ந்வ஡கபின் இபே஥லுக்கு த஡ன், ஋லு஥ிச்வசச்சோறுடன் கனந்து குவநந்஡ 
அப஬ில் பகோடுத்து஬஧த் ஡஠ிப௅ம். 
 
 இவபத்஡ உடம்திணபேக்கு இ஡஦த்வ஡ப் தனப்தடுத்஡ த஡வண ஬஫ங்கி ஬஧னோம். 
 
 ஥துத஥க த஢ோ஦ிற்கோக ஬஫ங்கப்தடும் ஥பேந்துகபில் த஡ன் ப௃க்கி஦ப் 
பதோபேபோகச் தசர்க்கப்தடுக்கின்நது. 
 
 தகோவ஫வ஦ ஢ீக்கும் , புண்஠ோற்றும் ஥பேந்துகபில் தசர்க்கப்தடுகிநது.2 
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HONEY 
Phytochemicals: 
 
Honey is known to be rich in both enzymatic and non-enzymatic antioxidants, including 
catalase, ascorbic acid, flavonoids and alkaloids.
74,75,76 
 
Scientific validation: 
Wound healing property: 
 This article deals the wound healing property of the honey.The pharmacological 
activity of honey balm, its influence on wounds healing processes and the rate of scar 
formation in comparison with control groups were assessed. Clinical and histopathological 
studies showed that honey balm not only shortened the period of wound healing but also 
had a positive impact on the general health condition of the animals.
77
 
Antiproliferative Effect: 
 This review has clearly demonstrated certain honey polyphenols tested in laboratory 
setups showed to be a promising pharmacological agent for inhibiting cancer cell 
proliferation.
78 
Antifungal activity: 
              This paper revealed the antifungal activity of honey.The honey samples were 
examined for antifungal activity against Aspergillus niger, Aspergillus flavus, Penicillium 
chrysogenum, Microsporum gypseum, Candida albicans, and Saccharomyces sp. Minimum 
inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of the honey 
were also determined. Results obtained reveal that the honey samples showed varying levels 
of inhibitory activity at various concentrations against the fungi tested with zones of 
inhibition increased with increasing honey concentration.
79
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3.6 ப஬ல்னம் 
ப஬ல்னம் தித்஡குன் ஥த்வ஡ப் ததோக்கும்.ஆணோல் ஍஦த்வ஡ப௅ம், 
஬஦ிற்றுப்புழுக்கவபப௅ம், ஢ீரி஫ிவு த஢ோவ஦ப௅ம் உண்டோக்கும்28. 
 
“குன்஥ தித்஡ம் ததோக்கு஥஡ி தகோவ஫஡வண ப௅ண்டோக்குந் 
  துன்஥னத்துட் கீடத்வ஡த் த஡ோற்று஬ிக்கும்- ஢ன்வ஥ததோல் 
  ப஥ல்ன஥து ஢ீவ஧ ஬ிவப஬ிக்கும் ஥ோ஥து஧ 
  ப஬ல்னப஥ண ஢ோல௃ம் ஬ிபம்பு”. 
           (அ.கு) 
 
Scientific validation: 
  This article reveals genotoxic effects induced by arsenic through parenteral 
administration and ameliorate by jaggery. Chromosomal aberrations were more pronounced 
in arsenic-treated mice, while supplementation of jaggery with arsenic reduced the 
incidence of the aberrations. The outcome of the study showed that Jaggery the natural 
functional food has the efficiency to encounter the genotoxic effects induced by arsenic.
80
 
  This article showed Fresh goat tissues (tongue) were fixed separately with buffered 
10% formalin (positive control), honey, sugar syrup, jaggery syrup, and distilled water 
(negative control). 24 h fixation was done at room temperature followed by conventional 
processing and routine H and E staining. The stained sections were assessed for cytoplasmic 
and nuclear detail by three pathologists under the light microscope and were graded 
accordingly. The preservation of tissue by honey, sugar, and jaggery syrup was comparable 
to that of formalin. Among the three natural fixatives, jaggery syrup excelled. Hence, it can 
be considered as an equally effective formalin substitute.
81 
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CHAPTER IV 
MATERIALS AND METHODS 
 
4.1. PREPARATION OF THE TEST DRUG: 
4.1.1. COLLECTION OF RAW DRUGS: 
             Ayam was collected from Trichy river bed and other herbal drugs such as 
Keezhaneli,Nellikai and Karisalai were collected from the Tambaram market, Chennai. 
4.1.2. AUTHENTICATION: 
The mineral drug Ayam were identified and authenticated by Lecturer, Department 
of Gunapadam , National Institute of Siddha , Chennai-47. 
            The herbal drugs Nellikai (Phyllanthus emblica ), Keezhkainelli(Phyllanthus nirui ), 
Karisalai (Eclipta alba) were identified and authenticated by Assistant Professor, 
Department of Medicinal Botany, National Institute of Siddha, Chennai-47.   
4.1.3.METHODS OF PURIFICATION: 
1.Purification of Ayam: 
The juice of jamun fruit (Syzigium cumini) was poured over the iron powder till the 
powder is immersed in the juice and then kept in sunlight until the juice completely dried 
after that the dried iron powder was washed. This process is repeated six times to get the 
purified iron, every time used fresh juice of Syzigium cumini
2
. 
2. Purification of Nellikai: 
            Remove the seeds from Nellikai.
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4.1.4. METHOD OF AYA PODI ELAGAM PREPARATION: 
Ingredients: 
  Purified Ayapodi (Iron powder)       -   280 g 
 
             Nellikai chaaru            -   140 g 
             (Phyllanthus emblica juice) 
 
  Keezhkainelli chamoolamchaaru      -   140 g                       
  (Phyllanthus nirui whole plant extract)  
 
  Karisalai chaaru           -   105 g 
  (Ecliptaalba plant extract)    
 
  Purified honey            -    87.5 g 
 
  Jaggery (vellam)      -    70 g 
 
Method of preparation:  
             Mix all the extracts mentioned above the purified iron was ground in a mortar for 
tweleve hours adding the mixture of the extracts. The resultant product was kept in an iron 
pot;mix it well in the remaining part of the extracts then heat the pot slowly. Stir well the 
iron paste with honey and jaggery (vellam).When cool, pour the paste into a porcelain 
vessel and keep it for use. 
Therapeutic uses:   
        It cures Pithapandu (Anaemia), Pithavettai, and Manjal noi (Jaundice).  
Therapeutic dosage: 
        The dose is 2.5 g  to 5 g twice daily after food. 
Duration: 1 Mandalam (48 days) 
10 
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INGREDIENTS OF AYAPODI ELAGAM 
Nellikai      Karisalai  
 
Keezhanelli        Vellam 
 
Honey 
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Before Purification of Ayam                    Purification process of Ayam   
 
 
 
 
 
 
 
 
 
 
After Purification of Ayam    Medicine Preparation  
 
 
 
 
 
49 
 
Ayapodi Elagam 
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4.2. ANALYTICAL STUDY OF AYAPODI ELAGAM 
             The Ayapodi Elagam was subjected to following analytical studies like 
physicochemical analysis, Biochemical Analysis, Phytochemical analysis and Spectroscopic 
analysis by using sophisticated instruments.
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4.2. STANDARDIZATION OF AYAPODI ELAGAM  
 
4.2.1. QUALITATIVE ANALYSIS PHYSICO-CHEMICAL ANALYSIS OF 
AYAPODI ELLAGAM 
          The physico- chemical properties of Ayapodi Elagam was carried as per standard 
procedure at The Tamilnadu Dr.M.G.R.Medical University, Guindy, Chennai -32.  
1. Loss on Drying: 
An accurately weighed 2g of Ayapodi Elagam formulation was taken in a tarred 
glass bottle. The crude drug was heated at 105
0
C for 6 hours in an oven till a constant 
weight. Percentage moisture content of the sample was calculated with reference to the 
shade dried material.  
2. Determination of total ash: 
               Weighed accurately 2g of Ayapodi Elagam formulation was added in crucible at a 
temperature 600
0
C in a muffle furnace till carbon free ash was obtained. It was calculated 
with reference to the air dried drug.  
3. Determination of acid insoluble ash: 
               Ash above obtained, was boiled for 5min with 25ml of 1M Hydrochloric acid and 
filtered using an ash less filter paper. Insoluble matter retained on filter paper was washed 
with hot water and filter paper was burnt to a constant weight in a muffler furnace. The 
percentage of acid insoluble as was calculated with reference to the air dried drug. 
 4. Determination of water soluble ash: 
Total ash 1g was boiled for 5min with 25ml water and insoluble matter collected on 
an ash less filter paper was washed with hot water and ignited for 15min at a temperature 
not exceeding 450
0
C in a muffle furnace. The amount of soluble ash was determined by 
drying the filtrate. 
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5. Determination of water soluble Extractive:  
               5gm of air dried drug, coarsely powered Ayapodi Elagam was macerated with 
100ml of distilled water in a closed flask for twenty-four hours shaking frequently. Solution 
was filtered and 25 ml of filtrated was evaporated in a tarred flat bottom shallow dish, 
further dried at 100
0
 C and weighted. The percentage of water soluble extractive was 
calculated with reference to the air dried drugs.      
6. Determination of alcohol soluble extractive:  
               2.5 gm. of air dried drugs; coarsely powdered Ayapodi Elagam was macerated 
with 50 ml alcohol in closed flask for 24 hrs. With frequent shaking, it was filtered rapidly 
taking precaution against loss of alcohol. 10ml of filtrate was then evaporated in a tarred flat 
bottom shallow dish, dried at 100
0
C and weighted. The percentage of alcohol soluble 
extractive was calculated with reference to air dried drug. 
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4.2.2. BIO-CHEMICAL ANALYSIS:               
             The bio-chemical analysis of Ayapodi Elagam (A.E) was done in Biochemistry lab, 
National Institute of Siddha, Chennai-47. 
 
Preparation of Extract:    
5gm of Ayapodi Elagam (A.E) was weighed accurately and placed in a 250ml clean beaker 
and added with 50ml of distilled water. Then it was boiled well for about 10 minutes. Then 
it was allowed to cool and filtered in a 100ml volumetric flask and made up to 100ml with 
distilled water.  
S.NO EXPERIMENT OBSERVATION 
1. Appearance of sample Black in colour 
2. Test for Silicate:  
     a. A little (500mg) of the sample 
is shaken well with distilled water.  
     b. A little(500mg) of the sample is 
shaken well with con. HCl/Con. 
H2So4   
Sparingly  soluble 
3. Action of Heat:  
       A small amount (500mg) of the 
sample is taken in a dry test tube and 
heated gently at first and then strong 
White  fumes  evolved 
4. Flame Test:  
       A small amount (500mg) of the 
sample is made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame  
No bluish green flame appeared 
5. Ash Test:  
       A filter paper is soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into 
the Bunsen flame and ignited 
No  Yellow colour flame appeared 
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I. Test for Acid Radicals on Ayapodi Elagam 
 
 
 
S.NO EXPERIMENT OBSERVATION 
1. Test For Sulphate:  
    2ml of the above prepared extract is 
taken in a test tube to this added 2ml of 
4% dil ammonium oxalate solution 
No Cloudy appearance present 
2. Test For Chloride:  
    2ml of the above prepared extracts is 
added with 2ml of dil-HCl is added until 
the effervescence ceases off... 
No Cloudy appearance present 
3. Test For Phosphate: 
    2ml of the extract is treated with 2ml 
of dil. ammonium molybdate solution 
and 2ml of con.HNO  
Cloudy  yellow precipitate present 
4. Test For Carbonate:  
    2ml of the extract is treated with 2ml 
dil.magnesium sulphate solution 
Presence of cloud appearance 
5. Test For Nitrate:  
    1gm of the substance is heated with 
copper turning and concentrated H2SO4 
and viewed the test tube vertically down    
No brown gas is    evolved 
6. Test For Sulphide:  
    1gm of the substance is treated with 
2ml of con. HCL 
No rotten Egg Smelling gas is      
evolved 
7. Test For Fluoride & Oxalate:  
    2ml of extract is added with 2ml of dil. 
Acetic acid and 2ml dil. calcium chloride 
solution and heated. 
Absence of Cloudy        appearance 
8. Test For Nitrite:  
    3drops of the extract is placed on a 
filter paper, on that-2 drops of dil. acetic 
acid and 2 drops of dil. Benzidine 
solution is placed. 
No  characteristic changes 
9. Test For Borate:   
    2 Pinches (50mg) of the substance is 
made into paste by using dil. Sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No bluish green       colour flame 
appeared 
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II.Test for basic radicals on Ayapodi Elagam: 
S.NO EXPERIMENT OBSERVATION 
1. Test For Lead: 
          2ml of the extract is added with 
2ml of dil. Potassium iodine solution 
No yellow Precipitate is obtained. 
2. Test For Copper: 
       a. One pinch (50mg) of substance is 
made into paste with con. HCl in a watch 
glass and introduced into the 
nonluminous part of the flame 
No blue colour precipitate is 
formed. 
3. Test For Aluminum:  
        To the 2ml of extract dil. sodium 
hydroxide is added in 5 drops to excess 
Yellow colour Appearance 
4. Test For Iron: 
       A. To the 2ml of extract add 2ml of 
dil. Ammonium solution   
       B. To the 2ml of extract 2ml 
thiocyanate solution and 2ml of con 
HNo3 is added   
Brown precipitate is formed 
Red colour appearance 
5. Test For Zinc:  
       To 2ml of the extract dil .sodium 
hydroxide solution is added in 5 drops to 
excess and dil. ammonium chloride is 
added. 
White  precipitate is formed 
6. Test For Calcium:  
         2ml of the extract is added with 2ml 
of 4% dil. ammonium oxalate solution 
Cloudy appearance or white 
precipitate formation is present 
7. Test For Magnesium:  
              To 2ml of extract dil. Sodium 
hydroxide solution is added in drops to 
excess 
White precipitate is obtained 
8. Test For Ammonium: 
              To 2ml of extract 1 ml of 
Nessler's reagent and excess of dil. 
Sodium hydroxide solution are added. 
Brown colour is appeared 
9. Test For Potassium:  
               A pinch (25mg) of substance is 
treated off with 2ml of dil. Sodium nitrite 
solution an then treated with 2ml of dil. 
Cobalt nitrate in 30% dil. Glacial acetic 
acid.  
No yellowish precipitate is 
obtained. 
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III. Miscellaneous test for Ayapodi Elagam: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. Test For Sodium:  
            2 pinches (50mg) of the substance 
is made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner 
No yellow colour flame appeared 
11. Test For Mercury:  
            2ml of the extract is treated with 
2ml of dil. sodium hydroxide solution. 
No Yellow precipitate is obtained 
12. Test For Arsenic:  
            2ml of the extract is treated with 
2ml of dil .sodium hydroxide solution 
No brownish red precipitate is 
obtained 
S.NO EXPERIMENT OBSERVATION 
1. Test For Starch :  
          2ml of extract is treated with weak dil. 
iodine solution 
No Blue colour 
Formation is present 
2. Test For Reducing Sugar: 
 5ml of Benedict's qualitative solution is 
taken in a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The colour 
changes are noted. 
Brick red colour 
developed 
3. Test For The Alkaloids: 
            a) 2ml of the extract is treated with 2ml 
of dil. Potassium iodide solution. 
           b) 2ml of the extract is treated with 2ml 
of dil. Picric acid 
Yellow precipitation 
appears 
4. Test For Tannic Acid:  
           2ml of extract is treated with 2ml of dil. 
Ferric chloride solution 
No Black precipitate is 
obtained 
5. Test For Unsaturated Compound:  
          To the 2ml of extract 2ml of dil. 
Potassium permanganate solution is added 
Potassium 
permanganate is not 
decolourised 
6. Test For Amino Acid:  
           2 drops of the extract is placed on a 
filter paper and dried well. 20ml of Biurette 
reagent is added. 
Violet colour is not 
developed 
7. Test For Type Of Compound: 
       2ml of the extract is treated with 2 ml of 
dil .ferric chloride solution. 
Red colour developed 
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4.3.PHYTOCHEMICAL SCREENING – AYAPODI ELAGAM  
 
  The preliminary phytochemical screening test was carried out for each extract of 
Ayapodi Elagam as per the standard procedure at The Tamilnadu Dr.M.G.R.Medical 
University, Guindy, Chennai 32.
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 Detection of carbohydrate: 
 Extracts were dissolved individually in 5ml distilled water and filtered. The filtrates 
were used to test the presence of carbohydrates. 
a) Molisch‟s test: 
  To 2ml of sample extract, two drops of alcoholic solution of α-naphthol were 
added. The mixture was shaken well and a few drops of concentrated sulphuric acid were 
added slowly along the sides of test tube. A violet ring indicates the presence of 
carbohydrates. 
b) Benedict‟s test:  
  Filtrate were treated with Benedict‟s reagent and heated gently. Orange red 
precipitate indicates the presence of reducing sugars. 
Detection of glycosides: 
  Extract were hydrolyzed with dil.HCL and then subjected to test for glycosides. 
Modified Borntrager‟s test: 
   Extract were treated with Ferric Chloride solution and immersed in boiling water 
for about 5 minutes. The mixture was cooled and extracted with equal volumes of benzene. 
The benzene layer was separated and treated with ammonium solution. Formation of rose- 
pink color in the ammonical layer indicates the presence of anthranol glycosides. 
 
Detection of flavonoids: 
a) Alkaline reagent test: 
 
 Extract were treated with few drops of sodium hydroxide solution. Formation of intense 
yellow color, which becomes colorless on addition of dilute acid, indicates the presence of 
flavonoids. 
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b) Lead acetate test: 
  Extract were treated with few drops of lead acetate solution. Formation of 
yellow color precipitate indicates the presence of flavonoids.  
Test for Quinones: 
            Extract was treated with sodium hydroxide blue or red precipitate indicates the 
presence of Quinones. 
           The preliminary phytochemical studies of aqueous extract of Ayapodi Elagam were 
done using standard procedures. The results were presented in table. The present study 
reveals that the bioactive compounds were present in all the extracts of Ayapodi Elagam. 
4.4. THE MICROBIAL LOAD 
              The Microbial load was done in Regional Research Institute of Unani Medicine, 
Royapuram, Chennai-600 013. 
Analysis of Microbial Load as per WHO,2007
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Total viable aerobic count 
The total viable aerobic count (TVC) of the herbal material being examined is 
determined, as speciﬁ ed in the test procedure below, using one of the following methods: 
membrane-ﬁ ltration, plate count or serial dilution. Aerobic bacteria and fungi (moulds and 
yeasts) are determined by the TVC. 
          Usually a maximum permitted level is set for certain products, but when the TVC 
exceeds this level then it is unnecessary to proceed with determination of speciﬁc 
organisms; the material should be rejected without being subjected to further testing. 
Pretreatment of the test herbal material  
         Depending on the nature of the crude medicinal plant material, grind, dissolve, dilute, 
suspend or emulsify it using a suitable method and eliminate any antimicrobial properties by 
dilution, neutralization or ﬁltration. Either phosphate buffer pH 7.2; buffered sodium 
chloride-peptone solution, pH 7.0; or ﬂuid medium, used for the test, is used to suspend or 
dilute the test specimen. 
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Water-soluble materials  
Dissolve or dilute 10 g or 10 ml of plant material, unless otherwise speciﬁ ed in the test 
procedure for the material concerned, in lactose broth or another suitable medium proven to 
have no antimicrobial activity under the conditions of the test. Adjust the volume to 100 ml 
with the same medium. (Note that some materials may require the use of larger volumes.) If 
necessary, adjust the pH of the suspension to about 7. 
Test procedures 
Plate count  
For bacteria:  
Use Petri dishes 9–10 cm in diameter. To one dish add a mixture of 1 ml of the pre-treated 
plant material and about 15 ml of liqueﬁed casein-soybean digest agar at a temperature not 
exceeding 45 °C. Alternatively, spread the material on the surface of the solidiﬁed medium 
in a Petri dish. If necessary, dilute the material to obtain an expected colony count of not 
more than 300. Prepare at least two dishes using the same dilution, invert them and incubate 
them at 30–35 °C for 48–72 hours, unless a more reliable count is obtained in a shorter 
period of time. Count the number of colonies formed and calculates the results using the 
plate with the largest number of colonies, up to a maximum of 300. 
For fungi: 
         Use Petri dishes 9–10 cm in diameter. To one dish add a mixture of 1 ml of the 
pretreated material and about 15 ml of liqueﬁed Sabouraud glucose agar with antibiotics 
(also used is potato dextrose agar with antibiotics) at a temperature not exceeding 45 °C. 
Alternatively, spread the pretreated material on the surface of the solidiﬁed medium in a 
Petri dish. If necessary, dilute the material as described above to obtain an expected colony 
count of not more than 100. Prepare at least two dishes using the same dilution and incubate 
them upright at 20–25 °C for 5 days, unless a more reliable count is obtained in a shorter 
period of time. Count the number of colonies formed and calculates the results using the 
dish with not more than 100 colonies. 
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4.5. ANTIBACTERIAL ACTIVITY: 
        Antibacterial activity was done at M.K.University, Madurai – 625021. 
Antibacterial activity of compound towards human pathogenic bacteria was tested 
by serial dilution method on Luria Bertani (LB) agar plate. The human pathogenic Gram - 
positive bacteria such as Bacillus cereus MTCC 430 and Gram – negative bacteria 
Serratiamarcescens MTCC 4822 were obtained from Microbial Type Culture Collection 
(MTCC) Chandigarh, India. The above said human pathogens were inoculated in 20mL of 
sterile Nutrient broth and it was incubated at 37ºC for 12h. After incubation the bacterial 
culture were treated with compound (200µg/ml) and the culture was incubated for 6 hrs. 
After the treatment adds100µl of culture test tubes 101 to 107 was diluted and each 
dilutionwas taken 100 µl of sample spread on LB agar plates using with spreader. The plates 
were incubated for 24 hours at 37°C. After incubation, the results were observed plates and 
colonies were counted. 
4.6.SPECTROSCOPIC ANALYSIS: 
 Ayapodi Elagam was analyzed in the presence of heavy metals by using Atomic 
Absorption Spectrometer(AAS).This study was done at Asthagiri Herbal Research 
Foundation, 162-A, Perugudi Industrial Estate, Perungudi, Chennai-96.
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SEM and EDAX were done at M.K.University, Madurai – 625021.FT-IR was done at IIT 
Madras, Chennai. 
4.6.1. ATOMIC ABSORPTION SPECTROMETER (AAS) 
INSTRUMENT DETAILS:  
 UV-V is spectrometer AA240 series, UV 8500 Absorption Spectrometer (AAS) was 
used for the analysis. The operating parameters: 
Test Method      :  USP 231 USP 39 NF34 
Instrument    :  AAS 
Model     :  AA240 
Standard    :  Sigma standard Fe 
Sample preparation   :  For testing Fe- sample in Aqua Regia 
Lambda max    : Fe-248.3 nm 
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4.6.2. FT-IR: 
 
 
 
 
 
 
 
 
 Fourier transform infrared spectroscopy (FTIR) is a technique which is used to 
obtain an infrared spectrum of absorption or emission of a solid, liquid or gas. An FTIR 
spectrometer simultaneously collects high spectral resolution data over a wide spectral 
range. This confers a significant advantage over a dispersive spectrometer which measures 
intensity over a narrow range of wavelengths at a time.  
The term Fourier transform infrared spectroscopy originates from the fact that a 
Fourier transform (a mathematical process) is required to convert the raw data into the 
actual spectrum. For other uses of this kind of technique, see Fourier transform 
spectroscopy.  
The standard method to prepare a solid sample for FTIR spectrometer is to use KBr. 
About 2 mg of Ayapodi Elagam and 200 mg KBr are dried and ground. The particle size 
should be unified and less than two micrometers. Then, the mixture is squeezed to form 
transparent disc which can be measured directly. For liquids with a high boiling point or 
viscous solutions, it can be added in between two NACL pellets.  
           Then the sample is fixed in the cell by skews and measured. For a volatile liquid 
sample,  it is dissolved in CS2 or CCl4 to form 10% solution.  Then the solutions are injected 
into a liquid cell for measurement. Gas sample needs to be measured in a gas cell with two 
KBr windows on each side. That gas cell should first be vacuumed. Then the sample can be 
introduced into the gas cell for measurement. 
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4.6.3. SEM: 
 
 
 
 
 
 
A SEM is essentially a high magnification microscope, which uses a focused 
scanned electron beam to produce images of the sample, both top-down and, with the 
necessary sample preparation, crosses sections. The primary electron beam interacts with 
the sample in a number of key ways:-  
 A primary electron generates low energy secondary electron, which tends to 
emphasize the topographic nature of the specimen.  
 A primary electron can be backscattered which produces images with a high degree 
of atomic number (Z) contrast.  
 Ionized atoms can relax by electron shell-to-shell transitions, which lead to either X-
ray emission or Auger electron ejection. The X-ray emitted is characteristic of the 
elements in the top few µm of the sample.  
The SEM is carried out by using FEI-Quanta FEG 200-High Resolution Instrument.  
Resolution : 1.2 nm gold particle separation on a carbon substrate  
Magnification:  From a min of 12X to greater than 1, 00,000X 
Application :  To evaluate grain size, particle size distributions, material homogeneity  
  and intermetallic distributions.    
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4.7. TOXICOLOGICAL EVALUATION OF AYAPODI ELAGAM (A.E) 
 
            The following in vivo toxicity studies were carried out on Ayapodi Elagam (A.E) by 
World Health Organization (WHO) guideline
85.
 
 
Acute Oral Toxicity study (WHO Guideline)   
         Long term toxicity study (WHO Guideline)  
 
The toxicity studies were carried out at National Institute of Siddha. The study was 
done after getting permission from the Institutional Animal Ethics Committee.   
 
IAEC Approved No:  For acute and long term toxicity study – NIS/IAEC-I/2016/10  
 
For Acute and long term toxicity studies test animals were obtained from Tamil 
Nadu Veterinary and Animal Sciences University, Madhavaram. Animals were kept in 
animal house, National Institute of Siddha, Chennai.  
 
4.7.1. DESCRIPTION OF THE METHOD  
Selection of the animals:  
 Animals were selected as per guideline. Healthy adult animals of Wistar albino rat, 
both male and female rats were used for acute oral toxicity study and Long term toxicity 
study. The female animals used in the studies were nulliparous and non-pregnant.  
 
Housing and feeding conditions:  
Tempereture:In the experimental animal room: 22ºC (± 3ºC) 
 
Humidity: 60 ± 10 %  
 Lighting   : Artificial, the sequence being 12 hours light, 12 hours dark. 
 
The animals were housed in polypropylene cages provided with bedding of husk. 
The animals had free access to RO water. For feeding, Standard pellet diet (bought from 
SaiMeera foods pvt. Ltd, Bangalore) was used.  
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Preparation of animals:                      
 
The animals were randomly selected, to permit individual identification by cage 
number and individual marking on the fur of each animal was made with picric acid. The 
animals were kept in their cages for 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions. The principles of laboratory animal care were followed.  
 
Test Substance:         
Ayapodi Elagam (A.E) was black in colour, without taste and odour. The drug was 
dissolved in saline to obtain and ensure the uniformity in drug distribution. 
 
Route of administration:     
          Oral route was selected, because it is the normal route of clinical administration.  
Preparation of doses:                   
          The stock solution was prepared freshly as dose per animal suspended in 1ml saline.   
PROCEDURE:  
4.7.2. ACUTE ORAL TOXICITY STUDY  
Test Animals: 
Species and strain      :  Wistar Albino rat 
 Sex                           :  Male and Female  
Age, Weight            :  6-8 weeks, 160-180 g 
 Test guideline         :  WHO guideline   
Groups/treatment      :  Grouped by randomization  
Duration of exposure to the  
“Ayapodi Elagam”(A.E)  :  Single dose  
Study duration     :  14 days 
 Number of animals                :  10 male, 10 female / group 
 Route of administration         :  Oral 
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Number of animals and dose levels:  
Animals were divided into two groups each group contains 5 male and 5 female 
rats.One group as control and the other as test group. Control group was treated with saline 
and other group was treated with test drug Ayapodi Elagam (A.E) ten times more then the 
therapeutic dose (5000mg per kg b.wt). 
 
No of animals used in Acute toxicity study: 
 
 
 
 
Administration of doses:  
            The test drug was administered in a single dose by using oral gavage. Animals were 
fasted prior to drug administration. Following the period of fasting, the animals were 
weighed and test drug was administered. The control groups received equal volume saline. 
The test drug was administered at 10 times the therapeutic dose (5000 mg / kg b.wt). The 
food was withheld for 3-4 hours after dosing the animal.  
Observations:  
       Observations were made and recorded systematically and continuously observed after 
the drug administration as per the guideline.  
 ½ hour, 1 hour, 2 hours, 4 hours and up to 24 hours observation. 
 All rats were observed twice daily for further 14 days. 
 Body weight were Calculated weekly once. 
 Feed and water intake were Calculated daily. 
Cage side observation   
                 The animals were monitored for behavioral parameters like Alertness, 
Aggressiveness, Piloerection, Grooming, Gripping, TouchResponse, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrhea, Writhing, Respiration, and Mortality. 
Groups No. of Rats 
Group I : Vehicle control (saline ) 5 male, 5 female 
Group II : Test drug (5000mg / kg b.wt) 5 male, 5 female 
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Gross necropsy:  
    At the end of the 14th day all the animals were sacrificed by using the injection of 
Pentothal sodium Gross necropsy includes examinations of the external surface of the body, 
all orifices, cranial, thoracic and abdominal cavities and their contents. The brain,eye, lungs, 
heart, spleen, liver, kidneys, adrenaland sex organs of all animals. 
4.7.3. LONG TERM TOXICITY STUDY OF AYAPODI ELAGAM
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Test animals:  
Species and strain     :  Wistar albino rats 
Sex                                  :  Male and Female 
Age, Weight                   :  6 -8 weeks, 160-180 g 
Test guideline                  :  WHO guideline 
Groups/treatment             :  Grouped by randomization 
Duration                          :  90 days 
Number of animals           :  10/group (5/sex) 
Route of administration   :  Oral 
 
 
Grouping of animals:  
 
Long term toxicity study was carried out at different dose levels. The animals in 
both sex was divided in four groups (group I, II, III & IV). Each group consists of 10 
animals (5 males and 5 females). 
 
         Group-I served as control and the other three groups II, III and IV for test drug of Low 
dose (450mg/kg/b.wt), Mid dose(900mg/kg/b.wt) and High dose(1800mg/kg b.wt) 
respectively[The low dose was calculated from the therapeutic dose (5g) and body surface 
area of rat (0.018). Calculation of low dose – 5000 × 0.018 = 90 mg/200 g of animal]  
 
 Low dose    =  90 × 5 = 450 mg/kgb.wt 
 Mid dose  =  low dose × 2  
   =   450 × 2 = 900 mg/kg b.wt 
 High dose  =  low dose × 4 
 High dose   =  450 × 4 = 1800 mg/kg b.wt 
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No of animals used for long term toxicity study: 
 
Administration of doses:       
The animals were dosed with the test drug daily for a period of 90 days. The test 
drug mixed with saline and was administeredby oral gavage, and this was done in a single 
dose to the animals once in daily for 90 days.  
Observations:  
Experimental animals were kept under observation throughout the course of study for 
the following  
 All rats were observed twice daily for 90 days. 
 Body weight were Calculated weekly once. 
 Feed and water intake were Calculated daily. 
Cage side observation    
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, Piloerection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, and Muscle relaxant, Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrhea, Writhing, Respiration, and Mortality.   
Laboratory Investigations:  
 On the 91st day, the animals were fasted overnight, then anesthetized to collect 
blood samples from the abdominal aorta in two tubes:  one with  EDTA  for hematological 
parameters, another one without any anticoagulant and was centrifuged at 4000 rpm at 4°C 
for 10 minutes to obtain the serum for biochemical parameters.  
 
Groups No of Rats 
Group I   : Vehicle control (Saline) 10 (5male, 5female) 
Group II  : (Test drug ) Low dose  (450 mg/kg b.wt) 10 (5male, 5female) 
Group III : (Test drug) Mid dose  (900 mg/kg b.wt) 10 (5male, 5female) 
Group IV : (Test drug) High dose  (1800 mg/kg b.wt) 10 (5male, 5female) 
67 
 
Hematological Investigations:  
Blood samples of control and experimental rats were analyzed for Haemoglobin 
(Hb), total Red Blood Corpuscles (RBC), Differential Count (DC), White Blood Corpuscles 
(WBC) count, Packed Cell Volume(PCV), Platelet, Mean Corpuscular Volume (MCV), 
Mean Corpuscular Hemoglobin (MCH),Mean Corpuscular Hemoglobin Concentration 
(MCHC) were calculated by auto analyzer.  
Biochemical Investigations:  
Serum samples of control and experimental animals were analyzed for, Bilirubin, 
BUN, Creatinine, Triglyceride, Total Cholesterol, HDL, LDL, VLDL, using standard 
methods. Activities of glutamate oxaloacetate transaminase/ Aspartate aminotransferase 
(SGOT/AST), glutamate pyruvate transaminase/ Alanine aminotransferase (SGPT/ALT) 
were estimated as per the colorimetric procedure.   
Necropsy:  
           All the animals were sacrificed on the 91st day except the high dose group four 
animals. The high dose group two male and two female animals were set as satellite group. 
The satellite group was sacrificed on after 30 days. Gross necropsy includes examinations 
of the external surface of the body, all orifices, cranial, thoracic and abdominal cavities and 
their contents. Brain, eye, lung, heart, spleen, liver, kidney, adrenal,sex organsand bone 
marrow of all animals were collected and sent for histopathological evaluation. 
 
Histopathology:  
           The organs included liver, kidney, spleen, brain, heart, lung, stomach and bone 
marrow of the animals were preserved, and they were subjected to histopathological 
examination.  
The organ pieces (35µm thick) of all the animals (control, high dose and satellite 
group) were preserved and fixed in 10% formalin for 24 hrs. Samples were dehydrated in an 
auto technic and then cleared in benzene to remove absolute alcohol.  Embedding was done 
by passing the cleared samples through three cups containing molten paraffin at 50
o
C and 
then in a cubical block of paraffin made by the “L” moulds. It was followed by microtome 
and the slides were Prepared then stained with Haematoxylin-eosin. 
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Bone Marrow Smear: 
   About 0.2 ml of smear aspirated from the femur thigh bone of the experimental 
animal was dropped onto the glass slide and made in to thin smear allow the smear to dry. 
Dried smear was stained with leishman stain and washed. Followed by this cedar wood oil 
was placed on to the smear and was observed microscopically.
86 
Statistical analysis:  
Findings such as body weight changes, food consumption, water intake, 
heamatology and biochemical analysis were subjected to One-way ANOVA Dennett‟s test 
using a computer software program followed by Graph Pad Instat-3.
87
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CHAPTER V 
 
RESULTS 
5.1. QUALITATIVE ANALYSIS 
A.PHYSICO-CHEMICAL ANALYSIS  
 
Table-1: Colour, Odour and nature of Ayapodi Elagam 
S.No Parameters Results 
1 Colour Black  
2 Odour Odourless 
3 Solubility  Soluble in water & milk  
 Insoluble in acetone& ether 
4 Nature Semisolid 
5. pH at 25°C(1%w/v 
solution)   
4.65 
 
From Table 1, The Organoleptic characters shows that Ayapodi Elagam is Black in colour 
and Odourless semisolid form of drug. It is soluble in water, milk and insoluble in acetone 
and ether and pH is acidic in nature. 
Table-2: Physico-chemical properties of Ayapodi Elagam 
S.NO Parameters Percentage 
1 Loss on drying  5.23% 
2 Total ash value 47.93% 
3 Acid insoluble ash  42.96% 
4 Water soluble ash  4.58% 
5 Water soluble extraction   37.18% 
6 Alcohol soluble extraction  14.1% 
 
From Table 2, The Physico-chemical analysis of Ayapodi Elagam explained in the 
parameters such as Moisture content, Total ash value, Acid insoluble ash, Water soluble 
ash, Water soluble extraction and Alcohol soluble extraction were within the normal limits. 
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B.BIO-CHEMICAL ANALYSIS:  
 
Table-3: Test for Basic radicals on Ayapodi Elagam  
 
S.No Procedures Ayapodi Elagam 
1 Test for Ammonium + 
2 Test for Sodium - 
3 Test for Magnesium + 
4 Test for Aluminium + 
5 Test for Potassium - 
6 Test for Calcium + 
7 Test for Ferrous iron + 
8 Test for Copper - 
9 Test for Zinc + 
10 Test for Arsenic - 
11 Test for Mercury - 
12 Test for Lead - 
(+ve /- ve present or  absent if component tested ) 
From Table 3, The Biochemical analysis for basic radical reveals that Ayapodi Elagam 
contains Ammonium, Magnesium, Aluminium, Calcium, Iron, and Zinc. 
Table-4: Test for Acidic radicals on Ayapodi Elagam  
S.No Procedures Ayapodi Elagam 
1 Test for Sulphate - 
2 Test for Chloride - 
3 Test for Phosphate + 
4 Test for Flouride&Oxalate - 
5 Test for Nitrate - 
6 Test For Carbonate + 
7 Test For Sulphide - 
8 Test For Borate - 
9 Test For Nitrite - 
( + ve /- ve present or  absent if component tested ) 
From Table 4, The Biochemical analysis for acid radicals reveals that Ayapodi Elagam 
contains Phosphate and Carbonate. 
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Table-5: Test for Miscellaneous on Ayapodi elagam 
S.No Procedures Ayapodi Elagam 
1 Test for Starch - 
2 Test for Reducing sugar + 
3 Test for Alkaloids + 
4 Test for Amino Acids  - 
5 Test for Tannic acids - 
6 Test For Unsaturated 
Compound 
                            - 
7 Test for type of compounds Anti pyrine, Aliphatic amino acids 
and meconic acid are present 
( + ve /- ve present or  absent if component tested ) 
From Table 5, The Biochemical analysis for Miscellaneous reveals that Ayapodi Elagam 
contains Reducing sugar,Alkaloids, Anti pyrine, Aliphatic amino acids and Meconic acid 
are present. 
 
 
C.PHYTOCHEMICAL ANALYSIS: 
Table 6, Test for phytochemical screening on Ayapodi Elagam  
S.No Phytochemicals Test name H2O ext. 
1 Alkaloids  Mayer‟s  Test -ve 
Wagner‟s  Test -ve 
2 Carbohydrates  Molisch‟s Test  +ve 
Benedict‟s Test +ve 
3 Glycosides  Modified Borntrager‟s Test +ve 
Keller killian Test  -ve 
4 Saponin  Froth Test -ve 
Foam Test -ve 
5 Phytosterol  Salkowski‟s Test -ve 
6 Phenols  Ferric Cholride Test -ve 
7 Tannins  Gelatin Test -ve 
8 Flavonoids  Alkaline reagent Test +ve 
Lead acetate Test +ve 
9 Proteins & amino acids  Xanthoproteic Test -ve 
10 Diterpenes  Copper acetate Test -ve 
11 Gum &Mucilage  Extract + alcohol -ve 
12 Fixed oil &Fat  Spot Test -ve 
13 Quinones  NAOH + Extarct +ve 
 
( + ve /- ve present or  absent if component tested ) 
From the table 6, phytochemical screening shows presence of Carbohydrates,Glycosides, 
Flavonoids and Quinones.  
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D. MICROBIAL LOAD FOR AYAPODI ELAGAM 
Table 7, Microbial load for Ayapodi Elagam 
S.No Parameters 
Result 
 
WHO Permissible 
Limits (Internal use) 
1 Total Bacterial Count 
(TBC) 
Less than 1 cfu/gram Maximum 10
5 
per/g 
2 Total Fungal Count(TFC) Less than 1 cfu/gram Maximum 10
3
per/g 
3 Enterobacteriaceae Absent Maximum 10
3
per/g 
4 Escherichia coli Absent Maximum 10per/g 
5 Salmonella Spp Absent None 
6 Staphylococcus aureus Absent None 
7 Pseudomonas aeruginosa Absent None 
 
From the Table 7, Microbial Load for Ayapodi Elagam the Total Bacterial Count and Total 
Fungal Count was with in the limit.Enterobacteriaceae, Escherichia coli,Salmonella 
Spp,Staphylococcus aureus, P.seudomonas aeruginosawere absent as per WHO guideline.    
E. ANTI-BACTERIAL ACTIVITY: 
 The compound against S.marcescens MTCC 4822 showed the bacterium 
uncountable colonies (Too Numerous To Count (TNTC)) was grown on LB agar plates 
compared with control. B. cereus MTCC 430 towards the compound, bacterial colonies 
reduced in each dilution and colony was counted. 
Figure 1: Colonies growth on LB agar plates in various dilutions 
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Table 8, Anti-bacterial activity of Ayapodi Elagam  
S. No. Human Pathogens 10
1 
10
2
 10
3
 10
4
 10
5
 10
6
 10
7
 
1. Sterratia marcescens TNTC TNTC TNTC TNTC TNTC TNTC TNTC 
2. Bacillus cereus TNTC TNTC TNTC 162 29 5 3 
TNTC – Too Numerous To Count 
From the Table 8, The Ayapodi Elagam has anti-bacterial activity against B.cereus. 
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5.2. SPECTROSCOPIC ANALYSIS: 
A. ATOMIC ABSORPTION SPECTROSCOPY 
Iron content of Ayapodi Elagam was analyzed by AAS this result is  
Fe content in the sample --- 12.94% 
B. SCANNED ELECTRON MICROSCOPY  
Determination of Particle size onAyapodi Elagam 
Figure 2. SEM image of Ayapodi Elagam  
 
 
 
 
 
 
 
 
 
 
 
 
 
Results:   
Particle Size  :  Micro size 
Shape   :  Irregular  
Surface  :  Smooth  
Distribution  :  Aggregate  
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C. FT-IR Analysis of Ayapodi Elagam 
                           Graph 1 – FT-IR graph of Ayapodi Elagam 
 
 
 
 
 
 
 
 
 
 
 
Graph 1. Shows the FTIR spectrum of the Ayapodi Elagam sample and its 
functional groups. Before transfer, the bands from 3020 to 2952 cm−1 are ascribed to the 
stretching vibrations of the C–H bond of organic compounds. The band at 1140 cm−1 is 
assigned to the stretching vibration of the C–O bond of oleic acid. The band at 1423 cm−1 
can be ascribed to the asymmetric and symmetric stretches of COO–, indicating that the 
acid chain is attached to the Fe3O4. The strong absorption band at 599 cm−1 is assigned to 
Fe–O vibrations of Fe3O4. There is a slight decrease in the bands intensity at 2510 cm−1, 
suggesting the reservation of N-H chains on the surface of Fe3O4. A band at 3437 cm−1 that 
corresponds to the vibration of O–H is enhanced due to absorbed water on the surface after 
transfer. 
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D. EDAX  For Ayapodi Elagam: 
Figure 3. EDAX image for Ayapodi Elagam  
Area 485 
 
 
 
 
 
 
 
 
 
 
 
Graph 2 – EDAX  graph for Ayapodi Elagam  
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EDAX  analysis for Ayapodi Elagam Sample 
Element Weight % Atomic % Net Int. Error % 
C K 20.47 46.05 661.48 10.27 
O K 12.06 20.36 892.55 8.63 
SiK 1.19 1.15 190.61 10.60 
CaK 2.04 1.38 203.40 8.91 
FeK 64.23 31.07 2065.05 3.39 
 
EDAX analysis shows the elements present in the sample as shown in fig 3& table 9, 
Represents the weight and atomic percentage of sample. The presence of iron is 64 Wt% 
because using magnetic separation during sample preparation.The presence of Si and Ca is 
very small contribution by the presence of sand during sample collection and the herbal 
drugs Nellikai (Phyllanthus emblica ), Keezhkainelli (Phyllanthus nirui ), Karisalai(Eclipta 
alba ) in the sample.  
 
78 
 
5.3.ACUTE TOXICITY STUDY  
Table 10, Behavioural Signs of Acute Toxicity Study of Ayapodi Elagam 
Parameters 
30 mints 4 hrs 24 hrs 1
st
 week 2
nd
 week 
C T C T C T C T C T 
Skin & Fur N N N N N N N N N N 
Mucous Membrane N N N N N N N N N N 
Respiratory rate N N N N N N N N N N 
Heart rate N N N N N N N N N N 
Salivation & 
Lacrimation 
N N N N N N N N N N 
Lethargy Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Piloerection N N N N N N N N N N 
Urinary incontinence Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Defecation N N N N N N N N N N 
Sleep & Gait N N N N N N N N N N 
Tremors &Convulsion Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Mortality Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
 N – Normal, C – control, T – Test group. 
All the data were summarized in the form of (Table-10) revealed that there was no 
abnormal signs and behavioural changes in all animals at the dose level of 5,000 mg/kg 
body weight administered orally during the study period.   
             There was no mortality observed after dosing of Ayapodi Elagam upto 5000mg/kg 
body weight during the study period of 14 days. This indicates that the LD50 of Ayapodi 
Elagam is more than 5000mg/kg b.wt.  
            There were no changes in skin and fur, eyes and mucous membranes of all animals.  
The eating, drinking habit, sleep pattern, locomotion were normal in all animals and no 
changes in body weight as compared to control group.  
           At the end of the 14 the day  necropsy was performed and there was no abnormality 
seen in test groups as compared to control group during the examination. 
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LONG TERM ORAL TOXICITY STUDY 
5.4.1. FOOD INTAKE OF ALBINO RATS EXPOSED TO AYAPODI ELAGAM 
Food consumption ofthe animals no significant difference in food intake the test 
group animals were observed when compared with control group during the study period. 
(Table 11) but they were within physiological limit.  
Table 11, Food (mg/day) intake of albino rats exposed to Ayapodi Elagam 
Dose (mg/ 
day) 
Control Low dose Mid dose High dose 
Ist day 46.7±10.4 49.3±19 48.3±12.6 47±10.4 
18
th
 Day 53.3±12 54.7±10.01 55±5.0 56.3±12.4 
36
th
 day 56±15.6 56±11.53 57.3±11.23 59.6±10 
54
th
 day 58±15.14 58.6±13.3 57.6±13.7 59±15.7 
 72
nd
  day 60.3±13.3 59.3±15.8 59.3±13.3 60±13.2 
90th day 62±15 61±13.9 62±11 61±12.3 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Figure 4: Food (mg/day) intake of albino rats exposed to Ayapodi Elagam 
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5.4.2.WATER INTAKE OF ALBINO RATS EXPOSED TO AYAPODI ELAGAM 
 Water consumption of both control and test groups animal shows normal 
physiological limit throughout the study period.  
Table 12, Water (ml/day) intake of albino rats exposed to Ayapodi Elagam 
Dose (ml/day) Control Low dose Mid dose High dose 
Ist day 73.3±30.5 76.7±25.16 80±26.5 80±17.32 
18
th
 Day 78.3±20.8 70.3±15.3 73.3±508 83.3±15.3 
36
th
 day 80.3±15.3 86.7±11.54 82±20 86.3±20.8 
54
th
 day 83.3±15.3 85.5±11 80±12 76.7±25 
72
nd
  day 86.6±11.54 90±10 92±10 95±15.3 
90
 th
 day 98.3±7.6 96.7±11.5 98±5.7 97.8±7.6 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
 
Figure 5: Water (ml/day) intake of of albino rats exposed to Ayapodi Elagam 
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5.4.3.BODY WEIGHT CHANGES OF ALBINO RATS EXPOSED TO AYAPODI 
ELAGAM 
 Body weight of both control and test dose group exhibited normal body weight 
throughout the study period. (Table 13)  
Table 13, Body weight (g) changes of albino rats (Male and Female) exposed to 
AyapodiElagam  
Body 
weight 
I
st
 day 18
th
 Day 36
th
 day 54
th
 day 72
nd
  day 90
th
 day 
Control 212±20.7 248.5±20.7 282.7±40 301.7±54 323.6±64.7 338.1±62 
Low dose 200±40.8* 218±41.1 240.5±60 256.4±70.3 280.1±77.4 300.5±78 
Mid dose 210.5±42.8 207.8±43.0 243.7±69.6 271.5±74.8 297.2±72.7 308.4±74 
High dose 209.3±29.6 212.1±29.7 256±50.65 271.9±60.2 291.1±73.9 302.3±74 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Figure 6: Body weight (g) changes of albino rats (male and female) exposed to Ayapodi 
Elagam 
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5.4.4. HAEMATOLOGICAL CHANGES OF ALBINO RATS EXPOSED TO 
AYAPODI ELAGAM 
 The results of the Haematological investigations conducted at the end of the study 
the groups revealed slightly significant changes in levels of haematological parameters 
when compared with control group and post retrieval group haematological parameters 
towards normal when compared with control group. (Table 14) 
Table 14, Effect ofAyapodi Elagam on Haematological Parameters 
Parameters Control Low dose Mid dose High dose 
Satellite 
group 
RBC (×10
6
µl) 7.4±0.4 7.6±0.30 7.43±1.34 7.13±1.18 6.6±1.05 
WBC (×10
3
µl) 9.2 ±2.05 8.92±1.2 8.89±2.16 9.15±2.17 7.9±0.9 
PLT (×10
3
µl) 797±108.3 725.±127.3 757.1±152.6 628.83±100.3 735.5±107.2 
HGB (g/dl) 13.58±2.32 13.48±2.01 13.4±1.51 12.61±1.9 14.9±2.3 
Neutrophils 
(10
3
/mm
3
) 
1.74±0.54 1.92±0.7 1.75±0.45 1.58±0.3 1.72±0.4 
Lymphocyte (%) 73.25±9.08 88.74±10.86
** 
78.88±8.55 89.35±7.34** 74.8±9.8 
Monocyte (%) 3.39±1.7 3.64±1.6 2.4±1.21 3.68±1.49 3.52±0.7 
Eosinophil‟s (%) 1.32±0.26 1.35±0.33 1.36±0.3 1.45±0.23 1.6±0.35 
Basophils (%) - 1 1 - 0 
MCH (pg) 20.05±3.01 17.93±3.8 18.65±4.2 19.23±3.70 17.85±3.15 
MCV (fl) 58.84±5.13 56.43±5.75 57.96±5.4 59.01±5.03 56.9±4.9 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01 
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Figure 7:Effect of Ayapodi Elagam on RBC 
 
 
 
 
Figure 8:Effect of Ayapodi Elagam on WBC 
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Figure 9:Effect of Ayapodi Elagam on Platelet count 
 
 
 
Figure 10: Effect of Ayapodi Elagam on Hemoglobin 
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Figure 11:  Effect of Ayapodi Elagam on Leucocytes 
 
Figure 12: Effect of Ayapodi Elagam on MCH 
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Figure 13: Effect of Ayapodi Elagam on MCV 
 
 
5.4.5. LIPID PROFILE ON AYAPODI ELAGAM 
Biochemical investigations were conducted at the end of the study and the results 
were recorded. In mid dose group showed significant changes present in biochemical 
parameters when compared with the control group. But the other group the values were in 
normal physiological limits. 
  Table 15, Effect of Ayapodi Elagam on Biochemical parameters 
 
Dose (mg/kg) Control Low dose Mid dose High dose 
Satellite 
group 
Total 
cholesterol 
(mg/dl)   
137.6±14.20 129.7±10.9 119.09±14.70* 135.8±19.4 148.32±19.45 
HDL (mg/dl) 59.4±8.53 56.9±5.30 60.9±8.3 61.2±8.08 59.75±8.6 
LDL (mg/dl) 62.5±9.64 53.9±9.70 42.7±11.6** 56.33±15.6 69.5±21.64 
VLDL (mg/dl) 15.6±2.50 18.91±4.93 15.5±3.5 18.33±3.7 19.07±2.14 
Triglycerides 
(mg/dl) 
38.5±10.34 36.8±8.40 32.1±9.3 41.33±8.9 36.25±3.8 
 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
55
55.5
56
56.5
57
57.5
58
58.5
59
59.5
MCV(fl)
Control
Low dose
Mid dose
High dose
Satellite group
87 
 
Figure 14: Effect of Ayapodi Elagam on Biochemical parameters 
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5.4.6. RENAL PARAMETERS ON AYAPODI ELAGAM 
The results  of the renal functions test conducted at the end of study  test groups does 
not have any significant changes in levels of renal parameters when compared with control 
group and post retrieval group renal function parameters towards normal when compared 
with control group. 
Table 16, Effect of Ayapodi Elagam on Renal Parameters 
Dose(mg/kg) Control Low dose Mid dose High dose Satellite 
group 
BUN(mg/dl) 15.9±3.01 15.7±4.8 15.8±5.0 14.33±6.74 
16.2±3.9 
Creatinine 
(mg/dl) 
0.7±0.12 0.8±0.11 0.7±0.2 0.8±0.15 
0.75±0.21 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01 
Figure15: Effect of Ayapodi Elagam on Renal parameters  
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Figure 16.Effect of Ayapodi Elagam on Creatinine 
 
5.4.7. HEPATIC PARAMETER OF AYAPODI ELAGAM 
The results of the liver function test conducted at the end of the study the satellite 
group revealedsignificant changes in liver parameters when compared with control 
group.Other test group liver function parameters were normal when compared with control 
group. 
Table 17, Effect of Ayapodi Elagam on Hepatic Parameters 
Dose (mg/kg) Control Low dose Mid dose High dose Satellite 
group 
Total 
Bilirubin(mg/dl) 
0.4±0.10 0.44±0.32 0.5±0.30 0.6±0.40 
0.45±0.13 
SGOT(U/L) 86.44±16.6 94.7±21.95 94±21.62 108.83±22.9 
137±37.12** 
SGPT(U/L) 28.7±7.8 30.9±5.7 32±9.2 33.7±5.5 
31.5±7.6 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01 
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Figure 17: Effect of Ayapodi Elagam on Hepatic Parameters 
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Histopathology of Brain (Male) 
 
a) Control (10 X)                      b) High dose( 10X)                c) Satellite group (10X) 
 
 
a) Control( 40X)                       b) High dose (10X)   c) Satellite group (10X) 
 
Report: 
Appearance of Hippocampal neurons was normal with dense network.Morphology 
of neurons in CA1, CA2 and CA3 zones are normal.Cerebellum showed normal architecture 
in both cortex and medulla where three layers of cerebellar cortex the molecular, purkinje 
and granular layers appeared clear and distinct without any changes in their cells any 
inflammatory cells or gliosis. 
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Histopathology of Brain (Female) 
a)  Control (10X)                      b) High dose (10X)                  c) Satillite group(10X) 
 
a) Control (40X)                      b) High dose (40X)                 c) Satellite group (40X)         
 
Report: 
Regular marginal alignment on the neurons with promising histology was 
observed.No sign of vascular congestion and edema.Cerebral region shows the neuronal 
populations within the brain are heterogeneous with scattered combination of medium- to 
large-sized neurons with prominent nucleus. 
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Histopathology of Heart (Male) 
 
a)Control (10X)                        b )High dose (10X)                  c) Satillite group(10X) 
 
   a) Control (40X)        b) High dose (40X)                    c) Satillite group(40X) 
 
Report: 
No evidence of necrotic myocardium . Appearance of fibrils and cross striations are 
equidistant.Fibres appears normal elongated and rod shaped.Myocardial cells appears 
normal with well-defined mycoplasma and prominent nucleus and nucleolus.Appearance of 
myocyte was normal. 
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Histopathology of Heart (Female) 
 
a) Control (10X)                       b) High dose (10X)                  c) Satillite group(10X) 
 
 
a)  Control (40X)                      b) High dose (40X)                c) Satellite group (40X)          
 
 
Report: 
Nucleus appears prominent with regular arrangement of fibres. No evidence of 
pyknotic nucleus.No evidence of collagen deposition in myocardium.Appearance of 
myocyte was normal.Myocardial fibres appear normal elongated and rod shaped. 
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Histopathology of Lung (Male) 
 
a) Control (10X)                    b) High dose (10X)                  c) Satillite group(10X) 
 
 
 
a) Control (40X)                         b) High dose (40X)              c) Satellite group (40X) 
 
Report: 
 Perivascular region appears normal.Alveolar septa and wall appeared widen and 
normal.No signs of lymphocyte cuffing.Arrangement of epithelial and muscular appears 
normal.Opening of lumen of blood vessels appears regular with no invasion of 
inflammatory cells.Bronchial blood vessels and connective tissue appears normal with no 
sings of pulmonary edema. 
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Histopathology of Lung (Female) 
 
a) Control (10X)                 b)High dose (10X)                      c) Satillite group(10X) 
 
a)  Control (40X)                 b) High dose (40X)                  c) Satellite group (40X)          
 
Report: 
Bronchial opening appears regular with no signs of infiltration. Appearance of 
alveolar network was normal. The  parenchyma appears normal with regular arrangement of 
alveoli and alveolar sac with no signs of lymphocyte infiltration and pulmonary 
fibrosis.Nucleus of type I and II alveolar cells looks normal. 
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Histopathology of Stomach (Male) 
 
a)  Control (10X)                b) High dose (10X)                  c) Satillite group(10X) 
 
         a)  Control (40X)                        b) High dose (40X)                 c) Satellite group (40X) 
 
Report: 
The continuity of mucosa was normal with no evidence of ulceration.Lamina propria 
appears normal with no evidence of infiltration and inflammation.Regular histology of Inner 
circular muscle (ICM), gastric pit (GP), and muscularis mucosae (MM) were 
observed.Gastric glands, gastric glands including secretary sheath appears normal. 
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Histopathology of Stomach (Female) 
 
a)  Control (10X)                    b)High dose (10X)  c) Satillite group(10X) 
 
 
a) Control (40X)                  b) High dose (40X)                   c) Satellite group (40X)          
 
Report: 
Mucosal wall appears normal with regular arrangement of connective tissue.No 
signs of ulcer and glandular degeneration were observed. Appearance of Sub-mucosa and 
gastric glands appear normal.Regular histology of Inner circular muscle (ICM), gastric pit 
(GP), and muscularis mucosae (MM) were observed. 
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Histopathology of Liver (Male) 
 
a)  Control (10X)                    b) High dose (10X)                 c) Satillite group(10X) 
 
a) Control (40X)                        b) High dose (40X)               c) Satellite group (40X) 
 
Report: 
Cytoplasm appears normal with widen portal tract. Appearance of portal vein, bile 
duct and hepatic artery was normal.Mild discrete cytoplasmic vacuoles and rare foamy 
cytoplasm were observed.The sinusoid appears widen with occasional bi nucleated 
hepatocytes. Diffused vaculoar changes  were observed in the mid zonal region. 
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Histopathology of Liver (Female) 
 
a) Control (10X)                   b) High dose (10X)                     c) Satillite group(10X)   
 
 
 
a) Control (40X)                    b) High dose (40X)                  c) Satellite group (40X)          
 
Report: 
Appearance of portal vein, bile duct and hepatic artery was normal.Hepatocellular 
architecture, including hepatic sinusoid and hepatic cord was normal.The parenchyma 
appears normal with no evidence of necrosis. Appearance of terminal hepatic venules 
(central veins) to the portal tracts was normal. 
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Histopathology of Kidney (Male) 
a) Control (10X)                               b) High dose (10X)                 c) Satillite group(10X) 
 
a) Control (40X)                             b) High dose (40X)                 c) Satellite group (40X)          
 
Report: 
Lumen of vessels and bowman‟s space appears normal. Appearance of proximal and 
distal convolutes tubules was normal with no evidence of atrophy.The lining of epithelial 
cells in the renal tubules showed mild pyknosis of the nuclei. 
 
 
 
 
 
 
102 
 
Histopathology of Kidney (Female) 
 
a) Control (10X)                   b) High dose (10X)                    c) Satillite group(10X)   
 
a) Control (40X)                    b) High dose (40X)                   c) Satellite group (40X)                   
 
Report: 
 Normal renal structure with rounded renal corpuscles formed of the Glomerulus (G) 
and the Bowman‟s capsule (B) surrounded with Proximal Convoluted Tubule 
(PCT).Normal renal structure with regular arrangement of  Distal Convoluted Tubule 
(DCT) and Collecting Duct (CD). 
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Histopathology of Spleen (Male) 
 
a)  Control (10X)                    b) High dose (10X)                   c) Satillite group(10X) 
 
a) Control (40X)                         b) High dose (40X)              c) Satellite group (40X)          
 
Report: 
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the samples. 
No abnormalities found in lymph node of both the samples. Discrete changes were observe 
in spleen follicle and in pulp. 
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Histopathology of Spleen(Female) 
 
a)  Control (10X)                        b)High dose (10X)                c) Satillite group(10X)   
 
a)  Control (40X)                    b) High dose (40X)                  c) Satellite group (40X)                   
 
Report: 
Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was 
normal with no significant signs of enlargement. Remarkable changes were observed in 
spleen architecture with increased number of megakaryocytes. Appearance of splenic 
sinuses, Splenic cord and endothelial orientation was normal. 
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Histopathology of Testes 
 
 
a)  Control (10X)                  b) High dose (10X)                      c) Satillite group(10X) 
 
a)  Control (40X)                   b) High dose (40X)                  c) Satellite group (40X) 
 
Report: 
Light microscopic observation of the sample showing normal interstitial connective 
tissue with ovoid or polygonal leydig cells.Presence of mature somatic cells project the 
perfect histomorphology of testicular cells was observed. Appearance of leydig cells, 
interstitial tissue , seminiferous tubule, Sertoli cells and spermatogonia were normal 
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Histopathology of Uterus 
 
a)  Control (10X)                  b)High dose (10X)                      c) Satillite group(10X)   
 
 
a) Control (40X)                     b) High dose (40X)                  c) Satellite group (40X)                   
 
Report: 
Endometrial stroma; G, gland; M, myometrium; P, perimetrium; L, lumen exhibits 
normal histological aspect of endometrium and myometrium.Appearance of uterine glands 
was normal. Endometrial gland, epithelium and blood vessels appears normal. 
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Histopathology of Ovary 
a)  Control (10X)               b) High dose (10X)                      c) Satillite group(10X)   
 
a)  Control (40X)                   b) High dose (40X)                  c) Satellite group (40X)                   
 
 
Report: 
Sequential arrangement of granulosa cells arounds oocyte was normal and 
regular.Follicular cells, cytoplasm and nucleus appears normal.Histopathological analysis of 
ovary showed normal corpus luteum and Primordial follicles with few mature ovarian 
follicles with no signs of abnormality.  
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MICROSCOPIC VIEW OF BONE MARROW SMEAR OF RATS 
EXPOSED TO AYAPODI ELAGAM 
LOW DOSE GROUP 
       Low Power Magnification (10X)           High Power Magnification (40X) 
 
 
 
 
 
 
 
 
MID DOSE GROUP 
         Low Power Magnification (10X)  High Power Magnification (40X) 
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HIGH DOSE GROUP 
 
    Low Power Magnification (10X)          High Power Magnification (40X) 
 
 
 
 
 
 
 
 
 
SMEAR STUDY REPORT 
Low Dose Group: 
 Bone marrow smear of Low dose reveals normal Eosinophilicmyelocyteand 
basophilicmyelocyte. 
 
Mid Dose Group: 
Increased network of erythroblastic islets were observed in mid dose. 
 
High Dose Group: 
 
Bulky prominent marrow with dense cellular portions were observed and active 
zones of erythropoiesis were observed in sample belong to HD. 
 
 
 
 
110 
 
CHAPTER VI 
DISCUSSION: 
 The Ayapodi Elagam is used for the treatment of PithaPandu, Pithavettai, and 
Kamalai etc., in Siddha system of medicine. One of the ingredients of this medicine was 
Iron (Ayam), has a long history in the treatment of anaemia among Siddha doctors in the 
Tamilnadu. 
 Literature reviews reveal that there was no such research has been done on Ayapodi 
Elagam. As an initial step in this present study a part of standardization of this drug 
•    AAS 
•    SEM 
•    EDAX 
•    Physiochemical 
•    Phytochemical analysis and Biochemical Analysis. 
Its safety has been confirmed through acute and long-term oral toxicity study as per 
WHO guideline. Standardization of the drugs means confirmation of its identity and 
determination of its quality and purity.
88
By the way of standardization metal based drugs 
can be evaluated for their performances, limitation, optimal dosage, contraindications and 
applications.
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Physiochemical analysis of Ayapodi Elagam reveals that the drug appears black in 
colour and semisolid in nature. Its pH valves were acidic in nature which is expected to 
have significant absorption in the stomach. 
 
The loss on drying at 105
0
c was 5.23% hence it does not allow any microbial 
contamination in the drug.   Extraction value determines the number of active constituents 
in a given amount of the formulation when extracted with a solvent media such as water and 
alcohol. The water-soluble and alcohol soluble extract values provide an indication of the 
extent of polar and non-polar compounds respectively present in Ayapodi Elagam. The 
extract values of Alcohol in Ayapodi Elagam is 14.1% and water is 37.18%.From the above 
result, we conclude that water is better solvent then alchohol. 
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Quality analysis of Ayapodi Elagam for acid radicals, basic radicals and other 
constituents demonstrates the presence of Ammonium, Magnesium, Aluminium, Calcium, 
Iron, Zinc, Phosphate, Carbonates, Reducing sugar, Alkaloids, Antipyrine, Aliphatic amino 
acids and Meconic acid are present. The presence of  Zinc and Aminoacids helps to increase 
the iron absorption in the body. Phytochemical screening shows the presence of 
Carbohydrates, Glycosides, Flavonoids and Quinones. (From,the table 6).  
 
The results of Atomic Absorption Spectrometric studies of Ayapodi Elagam for the 
determination of Iron prove that they are within the limit. The presence of Iron was found to 
be 12.94%. 
 
 Analysis of Ayapodi Elagam by Scanned Electron Microscopy revealed the size 
stabilization of particles on the process and the presence of micro size particles. The micro 
size particles can attach to the cell surface and can diffuse readily inside the cells.  Thus, the 
size of the particle is able to influence the efficacy.  The particles are irregular in shape with 
a smooth surface. The particles show the even distribution in the fields examined. 
 
The FTIR spectrum shows theAyapodi Elagam sample and its functional groups. 
Before transfer, the bands from 3020 to 2952 cm−1 are ascribed to the stretching vibrations 
of the C–H bond of organic compounds. The band at 1140 cm−1 is assigned to the 
stretching vibration of the C–O bond of oleic acid. The band at 1423 cm−1 can be ascribed 
to the asymmetric and symmetric stretches of COO–, indicating that the acid chain is 
attached to the Fe3O4. The strong absorption band at 599 cm−1 is assigned to Fe–O 
vibrations of Fe3O4. There was a slight decrease in the bands intensity at 2510 cm−1, 
suggesting the reservation of N-H chains on the surface of Fe3O4. A band at 3437 cm−1 that 
corresponds to the vibration of O–H is enhanced due to absorbed water on the surface after 
transfer.This result concluded the function group of Ayapodi Elagam was Fe3O4. 
 
EDAX analysis shows the elements present in the sample as shown in Fig. 2. The 
table represents the weight and atomic percentage of the sample. The presence of iron was 
64 wt% because using magnetic separation during sample preparation. The presence of Si 
and Ca was less amount contributed by the presence of sand during sample collection and 
the herbal drugs Nellikai (Phyllanthus Emblica), Keezhkainelli (Phyllanthusnirui), Karisalai 
( Eclipta alba ) in the sample.  
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 In acute toxicity study carried out as per WHO guideline there was no treatment-
related death or significance of toxicity developed in albino rats at dosage level 
5000mg/kg/b.wtthroughout the study period.Behavioural pattern, food and water intake was 
normal. Further, no gross pathological changes have been seen in the internal organs of both 
control and treated groups. Thus the LD50 value was found to be greater than 
5000mg/kg/b.wt. 
 
  To ensure the safety of Ayapodi Elagam long-term toxicity study was carried out as 
per WHO guideline. Except for hyperactivity at the time of drug administration, no other 
signs of toxicity and abnormal behavioural pattern were noted. After the blood collection, 
all the animals were euthanized for gross pathological examination of all major internal 
organs. The blood sample was sent to a lab for haematology and biochemical analysis. The 
organs were preserved in 10% buffered formalin solution before sending for 
histopathological study. All the reports were statistically analyzed. 
 
Ayapodi Elagam shows significant reduction in the body weight of the low dose and 
mid dose group animals when compared with the control group.During the study period 
their behavioural pattern, food and water intake were normal within the physiological limit. 
And this study reveals that it does not adversely affect the basal metabolic process of the 
test group animals. 
 
The hemopoietic system serves as an important target for the toxic chemicals and a 
sensitive index for pathological condition both in humans and animals. In haematological 
parameters, it had been observed that lymphocyte count was elevated after the 
administration of Ayapodi Elagam at the low dose and high dose group animals when 
compared to control group animals but the lymphocyte count was normal in post retrieval 
animals after one month of the drug with drawl.The other parameters such as Hb, RBC, 
WBC, DC, Platelet count, MCV, MCH and MCHC were normal in all the test group 
animals when compare to control group. The total cholesterol and LDL level were reduced 
in animal treated with the Ayapodi Elagam in the mid-dose group but they were in the 
normal limit. Transaminases (SGOT and SGPT) are good indicators of liver function and 
biomarkers to predict the possible toxicity of drugs. Any elevation pertaining to these 
enzymes indicate their outflow into the bloodstream due to damage in liver parenchymal 
cells. But, there was a marked increase in SGOT (Table – 17&Figure 15) in post retrieval 
group treated animals, when compared to control group, but it was also in the normal range 
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in other groups.In the present study there was no treatment-related abnormality in renal 
functions at all the test group animals (Table - 16& Figure14) and other hepatic parameters 
(Table 15& Figure13) were in normal limit. 
 
The histopathological study the organ such as brain, heart, kidney, liver, lung, 
spleen, stomach, uterus, ovary, testis and bone marrow were taken. There is no pathological 
changes observed in high dose and satellite group animals when compare to control group 
of animal.  
 
The smear study shows an increased network of erythroblastic islets was observed in 
mid-dose level. 
 
Above the results indicates the Ayapodi Elagam treated animals were normal when 
it is administered at higher dose level (1800mg/kg). 
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CHAPTER VII 
 
SUMMARY:       
    
 The Ayapodi Elagam is used for the treatment of anaemia, jaundice etc., mentioned 
in the Siddha literature. One of the ingredient of the drug was iron .It has a long history in 
the treatment of anaemia. The literature review reveals that there was no such research has 
been done in Ayapodi Elagam. An initial step in this study a part of standardization and 
preclinical safety evaluation of this drug was done. The raw drug ayam was collected from 
the river bed and other herbal drugs were procured from farms. They were identified and 
authenticated. The Raw drugs were purified and the medicine was prepared as mentioned in 
the Siddha literature.  On organoleptic examination, the finished product seems to be black 
in colour and semisolid in nature.   
 
 In the physicochemical analysis of  Ayapodi Elagam reveals a loss on drying at 
105
0
C of 5.23% w/w. Total Ash value, Acid insoluble Ash value, Water, and Alcohol 
Soluble Extractive values reveal the purity of the test drug. Qualitative Analysis of  Ayapodi 
Elagam demonstrates the presence of Ammonium, Magnesium, Aluminium, Calcium, Iron, 
Zinc, Phosphate, Carbonates, Reducing sugar, Alkaloids, Antipyrine, Aliphatic amino acids 
and Meconic acid.Phytochemical screening shows the presence of Carbohydrates, 
Glycosides, Flavonoids and Quinones. (From the table 6).The presence of Zinc and 
Aminoacids favour the iron uptake in the body. 
 
The results of Atomic Absorption Spectrometric studies of Ayapodi Elagam showed 
the presence of Iron was found to be 12.94% in the drug. 
 
Analysis of Ayapodi Elagam by Scanned Electron Microscopy revealed micro size 
particles and the particles are irregular in shape with a smooth surface.EDAX analysis 
shows the elements present in the sample was shown in Fig. 2. The table represents the 
weight and atomic percentage of the sample. The presence of iron was 64 wt %. The 
presence of Si and Ca was fewer amounts contributed. 
 
 The FTIR spectrum shows theAyapodi Elagamsample and its functional groups. 
Before transfer, the bands from 3020 to 2952 cm−1 are ascribed to the stretching vibrations 
of the C–H  bond of  organic compounds. The  band at  1140 cm −1 is assigned to the  
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stretching vibration of the C–O bond of oleic acid. The band at 1423 cm−1 can be ascribed 
to the asymmetric and symmetric stretches of COO–, indicating that the acid chain is 
attached to the Fe3O4. The strong absorption band at 599 cm−1 is assigned to Fe–O 
vibrations of Fe3O4. This result concluded the function group of Ayapodi Elagam was 
Fe3O4. 
 
 In acute toxicity study carried out as per WHO guideline there was no treatment 
related death or significance of toxicity and abnormal behavioural patten was developed in 
albino rats at dosage level 5000mg/kg/b.wt throughout the study period. Further, no gross 
pathological changes have been seen in the internal organs of both control and treated 
groups. Thus the LD50 valve was found to be greater than 5000mg/kg/b.wt. 
 
  Long-Term Toxicity Study, there was no significant changes in behavioural pattern, 
food intake and water intake during the study period. The haematological parameter shows 
the elevated lymphocyte count seen in the low and high dose group animals but it becomes 
normal in post retrieval group animals. In the lipid profile the mid dose group animals 
shows significant reduction in Total cholesterol and LDL level it was normal in post 
retrieval group animals. 
 
 The histopathological study the organ such as brain, heart, kidney, liver, lung, 
spleen, stomach, uterus, ovary, testis and bone marrow were taken. There was no 
pathological changes observed in high dose, satellite group when compare to control the 
group of animals. The smear study shows an increased network of erythroblastic islets was 
observed in mid-dose level and high dose level. 
 
  The above studies explained the qualitative of drug and presence of Fe3O4 as 
afunctional group of the study drug. They microparticles were also excised in the test drug 
by studying various analytical methods. From the safety study it reveals that the low dose 
and mid dose treated animals had some minimal haematological changes, but post retrieval 
animals had normal physiological parameters. The histopathological chances were not 
observed .So the drug may be eliminated after completion of the treatment period of the 
animals. The smear study shows an increased network of erythroblastic islets. So the drug 
can increase the RBC production in anaemic patients. These findings were craved the safety 
uses of the metallic preparation used in Siddha system of medicines. 
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     CHAPTER VIII 
CONCLUSION: 
  Ayapodi Elagam had been used by Siddhars for a long time to treat various diseases 
such as Anaemia, Jaundice etc.From the study the drug was acidic in nature so it can be 
easily observed in the stomach.The presence of zinc and amino acids also fovour the iron 
absoption in the body. Acute toxicity study showed that the test drug can be used upto the 
dose level of 5000mg/kg/b.wt. Ayapodi Elagam does not produces notable abnormalities 
were observed in all the group of animal. Hence we conclude that the dosage of Ayapodi 
Elagam 2.5 – 5 gm twice a day mentioned in Anubogavaithiya Navaneetham is a safer 
therapeutic dose for the human. The smear study shows increase erythroblastic islets were 
observed.It also helps to increase Haemoglobin level of the anaemic patient.So the Ayapodi 
Elagam can be more effective and safety drug for the anemic patiens.The author hopes that 
this study will be a foot print for further research on pharmacological activity, teratogenicity 
and clinical trials regarding Ayapodi Elagam. 
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